<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">80854</article-id><article-id pub-id-type="doi">10.7554/eLife.80854</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>MLL3 regulates the <italic>CDKN2A</italic> tumor suppressor locus in liver cancer</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-284218"><name><surname>Zhu</surname><given-names>Changyu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3583-3638</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-284217"><name><surname>Soto-Feliciano</surname><given-names>Yadira M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8523-7917</contrib-id><email>ysoto@mit.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-284219"><name><surname>Morris</surname><given-names>John P</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284220"><name><surname>Huang</surname><given-names>Chun-Hao</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-54520"><name><surname>Koche</surname><given-names>Richard P</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6820-5083</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284221"><name><surname>Ho</surname><given-names>Yu-jui</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284222"><name><surname>Banito</surname><given-names>Ana</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2188-0003</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216137"><name><surname>Chen</surname><given-names>Chun-Wei</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8737-6830</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284223"><name><surname>Shroff</surname><given-names>Aditya</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284224"><name><surname>Tian</surname><given-names>Sha</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-105370"><name><surname>Livshits</surname><given-names>Geulah</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284225"><name><surname>Chen</surname><given-names>Chi-Chao</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284226"><name><surname>Fennell</surname><given-names>Myles</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-119628"><name><surname>Armstrong</surname><given-names>Scott A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9099-4728</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-1758"><name><surname>Allis</surname><given-names>C David</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-284216"><name><surname>Tschaharganeh</surname><given-names>Darjus F</given-names></name><email>d.tschaharganeh@dkfz.de</email><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-5439"><name><surname>Lowe</surname><given-names>Scott W</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5284-9650</contrib-id><email>lowes@mskcc.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02yrq0923</institution-id><institution>Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0420db125</institution-id><institution>Laboratory of Chromatin Biology and Epigenetics, The Rockefeller University</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/042nb2s44</institution-id><institution>Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0130frc33</institution-id><institution>Department of Pharmacology, The University of North Carolina at Chapel Hill</institution></institution-wrap><addr-line><named-content content-type="city">Chapel Hill</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02yrq0923</institution-id><institution>Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jzgtq86</institution-id><institution>Dana-Farber Cancer Institute</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cdgtt98</institution-id><institution>Helmholtz-University Group &quot;Cell Plasticity and Epigenetic Remodeling&quot;, German Cancer Research Center</institution></institution-wrap><addr-line><named-content content-type="city">Heidelberg</named-content></addr-line><country>Germany</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/006w34k90</institution-id><institution>Howard Hughes Medical Institute</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Zhu</surname><given-names>Hao</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00t9vx427</institution-id><institution>University of Texas Southwestern Medical Center</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Golemis</surname><given-names>Erica A</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0567t7073</institution-id><institution>Fox Chase Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>01</day><month>06</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e80854</elocation-id><history><date date-type="received" iso-8601-date="2022-06-07"><day>07</day><month>06</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-05-31"><day>31</day><month>05</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-06-09"><day>09</day><month>06</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.06.07.495174"/></event></pub-history><permissions><copyright-statement>© 2023, Zhu, Soto-Feliciano, Morris et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Zhu, Soto-Feliciano, Morris et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-80854-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-80854-figures-v2.pdf"/><abstract><p>Mutations in genes encoding components of chromatin modifying and remodeling complexes are among the most frequently observed somatic events in human cancers. For example, missense and nonsense mutations targeting the mixed lineage leukemia family member 3 (MLL3, encoded by <italic>KMT2C</italic>) histone methyltransferase occur in a range of solid tumors, and heterozygous deletions encompassing <italic>KMT2C</italic> occur in a subset of aggressive leukemias. Although MLL3 loss can promote tumorigenesis in mice, the molecular targets and biological processes by which MLL3 suppresses tumorigenesis remain poorly characterized. Here, we combined genetic, epigenomic, and animal modeling approaches to demonstrate that one of the mechanisms by which MLL3 links chromatin remodeling to tumor suppression is by co-activating the <italic>Cdkn2a</italic> tumor suppressor locus. Disruption of <italic>Kmt2c</italic> cooperates with <italic>Myc</italic> overexpression in the development of murine hepatocellular carcinoma (HCC), in which MLL3 binding to the <italic>Cdkn2a</italic> locus is blunted, resulting in reduced H3K4 methylation and low expression levels of the locus-encoded tumor suppressors p16/Ink4a and p19/Arf. Conversely, elevated <italic>KMT2C</italic> expression increases its binding to the <italic>CDKN2A</italic> locus and co-activates gene transcription. Endogenous <italic>Kmt2c</italic> restoration reverses these chromatin and transcriptional effects and triggers Ink4a/Arf-dependent apoptosis. Underscoring the human relevance of this epistasis, we found that genomic alterations in <italic>KMT2C</italic> and <italic>CDKN2A</italic> were associated with similar transcriptional profiles in human HCC samples. These results collectively point to a new mechanism for disrupting <italic>CDKN2A</italic> activity during cancer development and, in doing so, link MLL3 to an established tumor suppressor network.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>liver cancer</kwd><kwd>MLL3</kwd><kwd>chromatin</kwd><kwd>cancer</kwd><kwd>tumor suppressor</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>P01 CA013106</award-id><principal-award-recipient><name><surname>Lowe</surname><given-names>Scott W</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R01 CA233944</award-id><principal-award-recipient><name><surname>Lowe</surname><given-names>Scott W</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>1K99GM140265-01</award-id><principal-award-recipient><name><surname>Soto-Feliciano</surname><given-names>Yadira M</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>1F32CA257103</award-id><principal-award-recipient><name><surname>Zhu</surname><given-names>Changyu</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000048</institution-id><institution>American Cancer Society</institution></institution-wrap></funding-source><award-id>PF-14-066-01-TBE</award-id><principal-award-recipient><name><surname>Morris</surname><given-names>John P</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>Helmholtz foundation</institution></institution-wrap></funding-source><award-id>VH-NG-1114</award-id><principal-award-recipient><name><surname>Tschaharganeh</surname><given-names>Darjus F</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100019346</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>P30 CA008748</award-id><principal-award-recipient><name><surname>Lowe</surname><given-names>Scott W</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Epigenetic regulator MLL3 is mutated and lost in human hepatocellular carcinoma due to its ability to activate a well-defined tumor suppressor and cell death in transformed cells.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Hepatocellular carcinoma (HCC) is a deadly primary liver cancer with a 5 year survival rate of only 18% (<xref ref-type="bibr" rid="bib34">Jemal et al., 2017</xref>). HCC is currently the fourth most frequent cause of cancer-related mortality worldwide, and its incidence continues to grow (<xref ref-type="bibr" rid="bib41">Llovet et al., 2021</xref>). Genomic alterations found in HCC are highly diverse and are characterized by promoter mutations in <italic>TERT</italic> (telomerase reverse transcriptase), amplifications, or chromosomal gains encompassing the <italic>MYC</italic> oncogene, activating hotspot mutations in <italic>CTNNB1</italic> (β-catenin), and inactivating mutations and deletions in the <italic>TP53</italic> and <italic>CDKN2A</italic> tumor suppressor genes (2017; <xref ref-type="bibr" rid="bib58">Schulze et al., 2015</xref>).</p><p>Among these alterations, genetic gain of <italic>MYC</italic> and inactivation of tumor suppressor p53 are known to cooperate to drive tumorigenesis in HCC (<xref ref-type="bibr" rid="bib44">Molina-Sánchez et al., 2020</xref>). Mechanistically, oncogenic MYC activation triggers increased expression of the tumor suppressor ARF, one of two proteins encoded in <italic>CDKN2A</italic> in alternative reading frames. ARF binds to the E3 ubiquitin ligase MDM2 to prevent p53 degradation, leading to apoptosis to restrain MYC-driven tumorigenesis (<xref ref-type="bibr" rid="bib42">Lowe and Sherr, 2003</xref>). However, it is unclear how the <italic>CDKN2A</italic> locus is regulated in response to MYC overexpression.</p><p>Beyond these well-studied drivers, HCC frequently harbors mutations in one or more chromatin modifying enzymes, including MLL3 (encoded by <italic>KMT2C</italic>; <xref ref-type="bibr" rid="bib24">Fujimoto et al., 2012</xref>; <xref ref-type="bibr" rid="bib35">Kan et al., 2013</xref>). MLL3 is a component of the COMPASS-like complex that has structural and functional similarities to the developmentally essential <italic>Drosophila</italic> Trithorax-related complex (<xref ref-type="bibr" rid="bib57">Schuettengruber et al., 2017</xref>). This multiprotein complex controls gene expression through its histone H3 lysine 4 (H3K4) methyltransferase activity, which establishes chromatin modifications most often associated with transcriptional activation (<xref ref-type="bibr" rid="bib60">Shilatifard, 2012</xref>). Most studies have shown that MLL3 and its paralog MLL4 (encoded by <italic>KMT2D</italic>) typically catalyze H3K4 monomethylation (H3K4me1) at enhancers (<xref ref-type="bibr" rid="bib29">Herz et al., 2012</xref>; <xref ref-type="bibr" rid="bib31">Hu et al., 2013</xref>), while the MLL1/2 complex is responsible for H3K4 trimethylation (H3K4me3) at promoters and enhancers in a locus-specific manner (<xref ref-type="bibr" rid="bib15">Denissov et al., 2014</xref>; <xref ref-type="bibr" rid="bib53">Rickels et al., 2016</xref>; <xref ref-type="bibr" rid="bib69">Wang et al., 2009</xref>).</p><p>While less characterized, MLL3/4 regulation of promoter activity is emerging as an additional mechanism connecting the COMPASS-like complex to gene expression. Some publications report that H3K4me1 enrichment at promoters has been associated with gene repression (<xref ref-type="bibr" rid="bib13">Cheng et al., 2014</xref>), and MLL3 inactivation decreases H3K4me3 levels at the promoters of metabolism-related genes in normal murine livers (<xref ref-type="bibr" rid="bib68">Valekunja et al., 2013</xref>) and human liver cancer cells (<xref ref-type="bibr" rid="bib2">Ananthanarayanan et al., 2011</xref>). Furthermore, a recent study in leukemia cells demonstrated that MLL3 and MLL4, in the absence of MLL 1/2 complex, are capable of binding to promoters to activate tumor suppressor genes (<xref ref-type="bibr" rid="bib61">Soto-Feliciano et al., 2023</xref>). These divergent results suggest that the genomic binding pattern and functions of MLL3 are highly context dependent.</p><p>Notably, HCC also harbors mutations in <italic>KMT2D</italic> (<xref ref-type="bibr" rid="bib14">Cleary et al., 2013</xref>), while KDM6A/UTX, an H3K27 demethylase within the COMPASS-like complex, has been functionally established as a potent tumor suppressor in pancreatic and liver cancers (<xref ref-type="bibr" rid="bib51">Revia et al., 2022</xref>). These observations suggest that epigenetic-based mechanisms of gene regulation controlled by the MLL3 complex may constrain HCC development. However, because chromatin regulators such as ARID1A often exhibit context-specific tumor suppressive and oncogenic roles in liver cancer development (<xref ref-type="bibr" rid="bib64">Sun et al., 2017</xref>), it is unclear whether MLL3 is a bona fide tumor suppressor in HCC. We therefore employed mouse models of HCC to investigate the molecular targets of MLL3 and the biological processes it affects.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>MLL3 is a tumor suppressor in <italic>Myc</italic>-driven liver cancer</title><p>To better understand the functional significance of genes commonly inactivated in HCC, including a number of chromatin regulators, we selected 12 genes with recurrent inactivating mutations in human HCC (<xref ref-type="bibr" rid="bib9">Cancer Genome Atlas Research Network, 2017</xref>; <xref ref-type="bibr" rid="bib1">Ahn et al., 2014</xref>; <xref ref-type="bibr" rid="bib24">Fujimoto et al., 2012</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>) and performed a CRISPR-based in vivo screen to determine whether they behave as tumor suppressors in HCC. Specifically, the screen tested whether loss of each of these 12 genes would drive hepatic tumorigenesis in cooperation with <italic>Myc</italic>—one of the most frequently gained and/or amplified oncogenes in HCC (<xref ref-type="bibr" rid="bib32">Huang et al., 2014</xref>). We applied hydrodynamic tail vein injection (HTVI) in wild-type mice to directly introduce genetic manipulations into adult hepatocytes in vivo (<xref ref-type="bibr" rid="bib6">Bell et al., 2007</xref>). We introduced both a transposon vector for stable genomic integration of oncogenic <italic>Myc</italic> cDNA and plasmids designed for transient expression of Cas9 and single guide RNAs (sgRNAs; a mix of two for each gene; <xref ref-type="fig" rid="fig1">Figure 1B</xref>; <xref ref-type="bibr" rid="bib38">Largaespada, 2009</xref>; <xref ref-type="bibr" rid="bib45">Moon et al., 2019</xref>; <xref ref-type="bibr" rid="bib66">Tschaharganeh et al., 2014</xref>; <xref ref-type="bibr" rid="bib73">Xue et al., 2014</xref>). 3 months after HTVI, only sg<italic>Kmt2c</italic> resulted in liver tumor formation with high penetrance (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>), suggesting that MLL3 likely acts as a tumor suppressor to constrain Myc-driven liver cancer. Supporting this idea, <italic>KMT2C</italic> mutations co-occur with <italic>MYC</italic> genomic gains and amplifications in human HCC tumors (<xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>MLL3 constrains <italic>Myc</italic>-driven liver tumorigenesis.</title><p>(<bold>A</bold>) Oncoprints displaying genomic mutations and deletions of <italic>KMT2C</italic> and <italic>TP53</italic>, gains and amplifications of <italic>MYC</italic>, and activating <italic>CTNNB1</italic> mutations in merged publicly available datasets (TCGA, MSK, INSERM, RIKEN, AMC, and MERCi) of 1280 sequenced hepatocellular carcinomas, and the table showing their relationships. p-Values were calculated by Fisher exact tests. (<bold>B</bold>) Schematic for hydrodynamic tail vein injection (HTVI) of gene delivery into murine livers. Vectors permitting stable expression of <italic>Myc</italic> transposon (top) and transient expression of Cas9 and single guide RNAs (sgRNAs) targeting putative tumor suppressors (bottom) via sleeping beauty transposase were introduced into hepatocytes by HTVI. (<bold>C</bold>) Survival curves of mice injected with <italic>Myc</italic> transposon and pX330 expressing two independent sgRNAs targeting <italic>Kmt2c</italic> after HTVI (<italic>Myc;</italic> sg<italic>Kmt2c</italic>.1, n=5; <italic>Myc;</italic> sg<italic>Kmt2c</italic>.2, n=5). <italic>Myc;</italic> sg<italic>Trp53</italic> (n=5), and <italic>Myc;</italic> sg<italic>Chrom8</italic> (n=5) serve as controls. Survival curves were compared using log-rank tests. (<bold>D</bold>) Representative images (left, liver macro-dissection, scale bar: 0.5 cm; right, H&amp;E staining, scale bar: 100 μm) of mouse liver tumors generated by HTVI delivery of <italic>Myc</italic> transposon and in vivo gene editing. The dashed lines indicate the boundaries between liver tumors and non-tumor liver tissues.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80854-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>In vivo screen identifies MLL3 as a tumor suppressor in Myc-driven liver cancer.</title><p>(<bold>A</bold>) Oncoprints displaying genomic gains and amplifications of <italic>MYC</italic> oncogene, and mutations and deletions of 12 candidate tumor suppressor genes in merged publicly available datasets (TCGA, MSK, INSERM, RIKEN, AMC, and MERCi) of 1280 sequenced hepatocellular carcinomas. (<bold>B</bold>) Liver tumor incidence in mice after hydrodynamic tail vein injection (HTVI) of <italic>Myc</italic> transposon and single guide RNAs (sgRNAs) targeting each candidate gene (n=4 mice per group).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80854-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Suppression of <italic>Kmt2c</italic> by CRISPR or RNAi promotes <italic>Myc</italic>-driven liver cancer.</title><p>(<bold>A</bold>) Survival curve of a second cohort of mice injected with <italic>Myc</italic> transposon and pX330 expressing two independent single guide RNAs (sgRNAs) targeting <italic>Kmt2c</italic> (<italic>Myc;</italic> sg<italic>Kmt2c</italic>.1, n=5; <italic>Myc;</italic> sg<italic>Kmt2c</italic>.2, n=5). <italic>Myc;</italic> sg<italic>Trp53</italic> (n=5), and <italic>Myc;</italic> sg<italic>GFP</italic> (n=5) served as controls. Survival curves were compared using log-rank tests. (<bold>B</bold>) Surveyor assay of PCR amplicons flanking predicted <italic>Kmt2c</italic> and <italic>Trp53</italic> CRISPR cleavage sites in <italic>Myc;</italic> sg<italic>Kmt2c</italic> and <italic>Myc;</italic> sg<italic>Trp53</italic> cells. The ratio of intensity of the lower bands (containing indels) to that of the upper band (untargeted) provides an estimate of the efficiency of CRISPR-Cas9 cleavage at the <italic>Kmt2c</italic> and <italic>Tpr53</italic> loci. (<bold>C</bold>) Sanger sequencing of the CRISPR-targeted <italic>Kmt2c</italic> locus from two independently derived cell lines using two different sg<italic>Kmt2c</italic>. The (protospacer adjacent motif)PAM-sequence is indicated in green; indels are indicated in red. (<bold>D</bold>) Schematic for hydrodynamic tail vein injection (HTVI) for in vivo gene silencing in mouse livers. HTVI was used to introduce transposons enforcing stable expression of <italic>Myc</italic> and (green fluorescent protein)GFP-linked, constitutive shRNAs(small hairpin RNAs) targeting genes of interest. (<bold>E</bold>) Survival curve of mice injected with transposon vectors expressing Myc oncogene and two independent shRNAs targeting <italic>Kmt2c</italic> (<italic>Myc;</italic> sh<italic>Kmt2c</italic>.1, n=6; <italic>Myc;</italic> sh<italic>Kmt2c</italic>.2, n=6), <italic>Trp53</italic> (<italic>Myc;</italic> sh<italic>Trp53</italic>, n=3), or Renilla luciferase (<italic>Myc</italic>; sh<italic>Ren</italic>, n=3). Survival curves were compared using log-rank tests. (<bold>F</bold>) Representative images of tumor nodules expressing shRNA-linked GFP in mice transduced with <italic>Myc;</italic> sh<italic>Kmt2c</italic>. BF: bright field. (<bold>G</bold>) <italic>Kmt2c</italic> mRNA expression measured by qPCR in the indicated tumor tissues. Values are mean ± SD from experimental triplicates in three different tumors of each group.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Original gel for surveyor assays in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-80854-fig1-figsupp2-data1-v2.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80854-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>MLL3 loss does not cooperate with CTNNB1 oncogene to drive liver cancer.</title><p>(<bold>A</bold>) Schematic for hydrodynamic tail vein injection (HTVI) of gene delivery into murine livers. Vectors permitting stable expression of constitutively active β-catenin (<italic>Ctnnb1-N90</italic>) transposon (top) and transient expression of Cas9 and single guide RNAs (sgRNAs) targeting putative tumor suppressors (bottom) via sleeping beauty transposase were introduced into hepatocytes by HTVI. (<bold>B</bold>) Survival curves of mice injected with <italic>Ctnnb1-N90</italic> transposon and pX330 expressing two independent sgRNAs targeting <italic>Kmt2c</italic> (<italic>Myc;</italic> sg<italic>Kmt2c</italic>.1, n=5; <italic>Myc;</italic> sg<italic>Kmt2c</italic>.2, n=5). <italic>Myc;</italic> sg<italic>Trp53</italic> (n=5), and <italic>Myc;</italic> sg<italic>Chrom8</italic> (n=5) served as controls.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80854-fig1-figsupp3-v2.tif"/></fig></fig-group><p>To validate and extend the results from the screen, we applied the same approach to test whether the screen phenotype could be recapitulated with oncogenic <italic>Myc</italic> and single <italic>Kmt2c</italic>-targeted sgRNAs (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Mice injected with an <italic>Myc</italic> cDNA transposon combined with either of two independent Cas9/<italic>Kmt2c</italic> sgRNAs (<italic>Myc</italic>; sg<italic>Kmt2c</italic>.1 or <italic>Myc</italic>; sg<italic>Kmt2c</italic>.2) developed liver tumors, with a slightly later onset and slightly longer survival than mice receiving the <italic>Myc</italic> transposon combined with an sgRNA targeting <italic>Trp53</italic> (<italic>Myc</italic>; sg<italic>Trp53</italic>; <xref ref-type="fig" rid="fig1">Figure 1C and D</xref>). In contrast, mice injected with <italic>Myc</italic> and a control sgRNA (sg<italic>Chrom8</italic>) did not succumb to disease over the observation period (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). These findings were confirmed in an independent cohort of mice (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2b</xref>). Analyses of tumor-derived genomic DNA revealed insertions and deletions (indels) in either <italic>Kmt2c</italic> or <italic>Trp53</italic> depending on the genotype of tumor-derived cells (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>). DNA sequencing of the CRISPR-targeted region from two independent <italic>Myc</italic>; sg<italic>Kmt2c</italic> tumors revealed indels predicted to generate premature stop codons (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>). In one case, the indel was heterozygous, implying that even partial suppression of <italic>Kmt2c</italic> can promote tumorigenesis. In support of this, GFP-linked <italic>Kmt2c</italic> shRNAs efficiently cooperated with <italic>Myc</italic> overexpression to drive liver cancer, producing tumors with 50–80% reduction in <italic>Kmt2c</italic> mRNA expression (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2D–G</xref>). sh<italic>Kmt2c</italic>.2 resulted in less potent knockdown than sh<italic>Kmt2c</italic>.1 yet produced faster tumor formation, suggesting that, as in acute myeloid leukemia (<xref ref-type="bibr" rid="bib12">Chen et al., 2014</xref>), MLL3 can likely act as a haploinsufficient tumor suppressor in liver cancer (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2E, G</xref>).</p><p>Apart from <italic>MYC</italic>, <italic>CTNNB1</italic> (β-catenin) is a frequently mutated oncogene in human HCC (<xref ref-type="bibr" rid="bib50">Rebouissou et al., 2016</xref>), although the co-occurrence between <italic>CTNNB1</italic> and <italic>KMT2C</italic> mutations was not statistically significant (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). To test whether MLL3 loss can cooperate with oncogenic <italic>CTNNB1</italic> to promote liver tumorigenesis, we performed analogous HTVI of a transposon vector expressing constitutively active β-catenin (<italic>Ctnnb1</italic>-N90; <xref ref-type="bibr" rid="bib67">Tward et al., 2007</xref>) in combination with <italic>Kmt2c</italic>- or <italic>Trp53</italic>-targeted sgRNAs (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref>). However, no tumor formation was observed in mice that received the <italic>Kmt2c</italic>-targeted sgRNAs (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3B</xref>), indicating that unlike p53, the tumor-suppressive role of MLL3 is specific to the oncogene and contexts.</p></sec><sec id="s2-2"><title>MLL3 loss alters the chromatin landscape of liver cancer cells</title><p>MLL3 and MLL4 are histone methyltransferases that can deposit the H3K4 monomethylation mark at genomic enhancers and intergenic regions during organ development (<xref ref-type="bibr" rid="bib31">Hu et al., 2013</xref>). However, more studies indicate that MLL3 and MLL4 are also capable of binding to promoter regions (<xref ref-type="bibr" rid="bib12">Chen et al., 2014</xref>; <xref ref-type="bibr" rid="bib16">Dhar et al., 2016</xref>; <xref ref-type="bibr" rid="bib70">Wang et al., 2010</xref>), especially in the context of cancer (<xref ref-type="bibr" rid="bib61">Soto-Feliciano et al., 2023</xref>). To determine the genomic binding patterns of MLL3 in HCC, we performed MLL3 chromatin immunoprecipitation (ChIP)-sequencing (ChIP-Seq) analysis in <italic>Myc</italic>; sg<italic>Kmt2c</italic> (sg<italic>Kmt2c</italic>.1 which generates heterozygous or homozygous indels) and <italic>Myc</italic>; sg<italic>Trp53</italic> liver cancer cell lines. Compared to the sg<italic>Trp53</italic> cells, sg<italic>Kmt2c</italic> cells had a marked reduction in MLL3 chromatin binding at a subset of genomic loci (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Approximately 40% of the peaks that were selectively lost in <italic>Kmt2c</italic>-deficient cells occurred at promoter regions, whereas unchanged MLL3 peaks between the two genotypes were more likely to be within intergenic regions (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Therefore, our data suggest that, beyond the canonical action of MLL3 at gene enhancers, MLL3 can also occupy promoter regions in <italic>Myc</italic>-induced liver cancer. Of note, the residual ChIP-seq signal observed in the sg<italic>Kmt2c</italic> cells most likely reflects the binding of MLL4 and/or remnant MLL3 since the antibody used in these experiments can recognize both MLL3 and MLL4 proteins (<xref ref-type="bibr" rid="bib19">Dorighi et al., 2017</xref>). Nonetheless, the downregulated peak signals in <italic>Myc</italic>; sg<italic>Kmt2c</italic> cells were specifically due to MLL3 disruption.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>MLL3 disruption alters the chromatin and transcriptional landscape of liver cancer cells.</title><p>(<bold>A</bold>) Tornado plots showing MLL3 chromatin immunoprecipitation-sequencing (ChIP-Seq) signal (peaks) that were down or remained unchanged in <italic>Myc</italic>; sg<italic>Kmt2c</italic> cells relative to <italic>Myc</italic>; sg<italic>Trp53</italic> cells. Center: transcriptional start site (TSS). (<bold>B</bold>) Alluvial plot showing the percentages of MLL3 ChIP-Seq peaks in different genomic elements in <italic>Myc</italic>; sg<italic>Kmt2c</italic> vs <italic>Myc</italic>; sg<italic>Trp53</italic> cells, including 16,999 peaks down, 48,815 peaks unchanged, and 265 peaks up in sg<italic>Kmt2c</italic> cells. Promoter regions were defined as TSS±2 kb. (<bold>C</bold>) Heatmaps of histone modification ChIP-Seq signals (H3K4me3, H3K4me1, H3K27ac, left panel) and MLL3 ChIP-Seq signal (right panel) at promoter or intergenic regions in three independent <italic>Myc;</italic> sg<italic>Kmt2c</italic> and <italic>Myc;</italic> sg<italic>Trp53</italic> liver tumor-derived cell lines. Cluster 1: loss of promoter and enhancer activity (loss of H3K4me3, H3K4me1, and H3K27ac); cluster 2: gain of enhancer activity (gain of H3K4me1 and H3K27ac); and cluster 3: gain of promoter activity (increase of H3K4me3). Representative top five loci for each cluster were listed on the right. (<bold>D</bold>) Volcano plot of differentially expressed genes revealed by RNA-sequencing of three independent <italic>Myc;</italic> sg<italic>Kmt2c</italic> and <italic>Myc;</italic> sg<italic>Trp53</italic> hepatocellular carcinoma (HCC) cell lines. Genes in sg<italic>Kmt2c</italic> cells with more than twofold expression change and exceeding adjusted p-value&lt;10<sup>–5</sup> are color-labeled (orange: upregulated; green: downregulated). Some differentially expressed genes are labeled with gene symbols, and p53 targets are bolded.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80854-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>MLL3 deficiency disrupts its binding at promoters in liver cancer cells.</title><p>(<bold>A</bold>) Tornado plots showing MLL3 chromatin immunoprecipitation-sequencing (ChIP-Seq) signals at promoter regions in <italic>Myc</italic>; sg<italic>Trp53</italic> and <italic>Myc</italic>; sg<italic>Kmt2c</italic> cells. Promoter regions were defined as transcriptional start sites (TSS)±2 kb. TES, transcription end sites. (<bold>B</bold>) Distribution graph of MLL3 binding peaks in different genomic regions and the changes based on the liver cancer genotypes.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80854-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>MLL3 disruption impacts transcriptional and histone modification profiles in liver tumors.</title><p>(<bold>A–C</bold>) Scatter plots comparing chromatin immunoprecipitation-sequencing (ChIP-Seq) signals for (<bold>A</bold>) H3K4me1, (<bold>B</bold>) H3K4me3, and (<bold>C</bold>) H3K27ac in <italic>Myc;</italic> sg<italic>Kmt2c</italic> (y-axis) and <italic>Myc;</italic> sg<italic>Trp53</italic> (x-axis) liver tumor-derived cell lines. (<bold>D and E</bold>) Scatter plots comparing RNA-seq (y-axis) and ChIP-Seq signals (x-axis) for (<bold>D</bold>) H3K4me3 and (<bold>E</bold>) H3K27ac in <italic>Myc;</italic> sg<italic>Kmt2c</italic> hepatocellular carcinoma (HCC) cell lines.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80854-fig2-figsupp2-v2.tif"/></fig></fig-group><p>Similar to the <italic>Drosophila</italic> Trithorax-related complex (<xref ref-type="bibr" rid="bib57">Schuettengruber et al., 2017</xref>), the mammalian MLL3 and MLL4 complexes facilitate gene transcription by establishing permissive modifications on histone H3K4 via the MLL3 and MLL4 methyltransferase (<xref ref-type="bibr" rid="bib60">Shilatifard, 2012</xref>). To determine whether MLL3 disruption impacts the local or global chromatin landscape of HCC cells, we performed ChIP-Seq analyses for H3K4 methylation and H3K27 acetylation in six independently derived tumor cell lines: three each for <italic>Myc</italic>; sg<italic>Kmt2c</italic> and <italic>Myc</italic>; sg<italic>Trp53</italic> (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Cluster analysis on genomic areas revealed three clusters of genomic loci that showed enrichment or depletion between <italic>Myc</italic>; sg<italic>Kmt2c</italic> and <italic>Myc</italic>; sg<italic>Trp53</italic> tumor cells for each tested histone modification (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A–C</xref>). Loci in cluster 1 (reduced H3K4me3, H3K4me1, and H3K27ac in sg<italic>Kmt2c</italic> cells) showed the most pronounced differences in chromatin modifications between the two liver tumor genotypes. In contrast, the loci in cluster 2 showed increased H3K4me1 and H3K27ac marks, most of which mapped to intergenic regions. The loci in cluster 3 showed increased H3K4me3 and included some p53 target genes such as <italic>Cdkn1a</italic> and <italic>Eda2r</italic>.</p><p>To determine whether these drastic changes in the chromatin landscape were associated with changes in MLL3 binding, we integrated the chromatin modifications results with our MLL3 ChIP-Seq results (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Interestingly, the loci in cluster 1, which displayed the most substantial changes in histone modifications, involved genes that showed enriched MLL3 binding in <italic>Myc</italic>; sg<italic>Trp53</italic> cells compared to the <italic>Myc</italic>; sg<italic>Kmt2c</italic> genotype. These data support a model whereby MLL3 binding to these loci facilitates the acquisition of a chromatin environment conducive for active gene transcription.</p></sec><sec id="s2-3"><title>MLL3 regulates specific tumor suppression programs in liver cancer cells</title><p>Transcriptional profiling helped hone in on potentially critical targets of MLL3. Specifically, we determined the output of these chromatin landscape changes by transcriptional profiling of the same set of <italic>Myc</italic>; sg<italic>Trp53</italic> and <italic>Myc</italic>; sg<italic>Kmt2c</italic> liver cancer cell lines described above. Despite the broad binding of MLL3 across the genome, we found only 248 differentially expressed genes (DEGs): 132 significantly upregulated (p&lt;0.05, log<sub>2</sub> fold-change &gt;2) and 116 significantly downregulated (p&lt;0.05, log<sub>2</sub> fold-change &lt;−2) in <italic>Myc</italic>; sg<italic>Kmt2c</italic> liver tumor cells compared to <italic>Myc</italic>; sg<italic>Trp53</italic> controls.</p><p>As predicted, transcripts encoding p53 and p53 target genes such as <italic>Ccng1</italic>, <italic>Cdkn1a</italic>, and <italic>Zmat3</italic> (<xref ref-type="bibr" rid="bib7">Bieging-Rolett et al., 2020</xref>) were upregulated in <italic>Myc</italic>; sg<italic>Kmt2c</italic> cells, consistent with nonsense-mediated decay of truncated p53 transcripts and a concomitant reduction in p53 effector genes. Strikingly, some of the downregulated genes in <italic>Myc</italic>; sg<italic>Kmt2c</italic> lines mapped to loci enriched in cluster 1, including <italic>Cdkn2a</italic>, <italic>Bmp6</italic>, and <italic>Lrp2</italic> (<xref ref-type="fig" rid="fig2">Figure 2C–D</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D, E</xref>). Of note, sg<italic>Kmt2c</italic> did not lead to compensatory changes in the transcript levels of other major components of the COMPASS-like complexes, including Mll4 (<italic>Kmt2d</italic>), Utx (<italic>Kdm6a</italic>), Mll1 (<italic>Kmt2a</italic>), and Mll2 (<italic>Kmt2b</italic>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>), suggesting that the alterations in MLL3 binding, histone modification, and transcription were specifically attributed to MLL3 disruption.</p><p>We reason that the mediators of MLL3 actions in tumor suppression should be within cluster 1 with reduced transcription and MLL3 binding in <italic>Kmt2c</italic>-deficient cells. To further characterize the gene repertoire directly regulated by MLL3 genomic binding, we integrated the results of MLL3 ChIP-seq and RNA-seq. Specifically, we selected downregulated DEGs that show concordant decreased binding of MLL3 in <italic>Myc</italic>; sg<italic>Kmt2c</italic> lines and subjected them to gene ontology analysis. Apart from the cluster 1 genes noted above, the integrative analysis revealed multiple MLL3-regulated tumor suppressive programs (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>), including both cell-autonomous mechanisms (cellular metabolism) and non-autonomous mechanisms (interaction with extracellular matrix and immune system).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>MLL3 regulates specific transcription programs including tumor suppressor CDKN2A.</title><p>(<bold>A</bold>) Network plot showing the major biological processes and related genes directly regulated by MLL3 binding. p-Values and cluster sizes were calculated by the integrative analyses of RNA-seq and MLL3 chromatin immunoprecipitation-sequencing (ChIP-Seq), as detailed in the Materials and methods. (<bold>B</bold>) Gene set enrichment analysis (GSEA) plots of transcriptional signatures derived from mouse hepatocellular carcinomas (HCCs; <italic>Myc</italic>; sg<italic>Kmt2c</italic> vs <italic>Myc</italic>; sg<italic>Trp53</italic>) against transcriptomics of HCCs with <italic>CDKN2A</italic> vs <italic>TP53</italic> mutations. (<bold>C</bold>) GSEA plots of transcriptional signatures derived from <italic>KMT2C</italic> mutated/deleted human HCCs against the ones with <italic>CDKN2A</italic> mutations or homozygous deletions. HCCs with <italic>TP53</italic> mutations were used as the controls for both comparisons. Normalized enrichment scores (NES) and false discovery rate (FDR) q-values were calculated by GSEA.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80854-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>MLL3 loss impacts specific transcription programs.</title><p>(<bold>A</bold>) Log2-transformed RNA-seq reads of <italic>Kmt2d</italic>, <italic>Kdm6a</italic>, <italic>Kmt2a</italic>, and <italic>Kmt2b</italic> in <italic>Myc;</italic> sg<italic>Trp53</italic> and <italic>Myc;</italic> sg<italic>Kmt2c</italic> liver cancer cells. (<bold>B</bold>) Gene ontology enrichment plot listing the biological processes regulated by direct MLL3 binding. Adjusted p-values and cluster sizes were calculated by the integrative analyses of RNA-seq and MLL3 chromatin immunoprecipitation-sequencing (ChIP-Seq), as detailed in Materials and methods.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80854-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title><italic>CDKN2A</italic> and <italic>KMT2C</italic> mutations cause similar transcriptional changes in human hepatocellular carcinoma (HCC).</title><p>(<bold>A</bold>) Oncoprints displaying the genomic alterations of <italic>MYC</italic> (gains and amplifications) and <italic>KMT2C</italic> and <italic>CDKN2A</italic> (mutations and deletions) in 1280 human HCCs, and a table showing their relationships. p-Values were calculated by Fisher Exact tests. (<bold>B</bold>) Gene set enrichment analysis (GSEA) plots of transcriptional signatures from <italic>RB1</italic> mutated/deleted human HCCs against the ones with <italic>CDKN2A</italic> mutations or homozygous deletions. HCCs with <italic>TP53</italic> mutations were used as the controls for both comparisons. Normalized enrichment scores (NES) and False discovery rate (FDR) q-values were calculated by GSEA.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80854-fig3-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title><italic>KMT2C</italic> and <italic>CDKN2A</italic> mutations result in similar transcriptomes in human HCC</title><p>One genomic locus that stood out in our integrative analysis was <italic>Cdkn2a</italic>, which encompasses both the p16/Ink4a and p19/Arf (p14 in human) tumor suppressors (<xref ref-type="bibr" rid="bib26">Gil and Peters, 2006</xref>). <italic>CDKN2A</italic> is located on the human chromosome 9p and is deleted or epigenetically silenced in many cancer types (<xref ref-type="bibr" rid="bib59">Sherr, 2012</xref>), including HCC (2017). While MLL3 likely regulates a plethora of genes that contribute to its tumor-suppressive potential, the well-defined and potent antitumor functions of <italic>Cdkn2a</italic>-encoded proteins make them attractive candidates as functionally relevant MLL3 effectors.</p><p>Furthermore, in our analysis publicly available genomic data on 1280 HCC samples, we found that <italic>CDKN2A</italic> alterations, like <italic>KMT2C</italic> alterations, showed significant co-occurrence with <italic>MYC</italic> gains and amplifications. However, we were unable to conduct a meaningful test of mutual exclusivity between <italic>CDKN2A</italic> and <italic>KMT2C</italic> alterations (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>), given the constraints of sample size and the modest frequencies of alteration in each gene. Further dissection of transcriptional profiling datasets from human and mouse HCCs harboring known gene alterations using gene set enrichment analysis (GSEA) revealed that human tumors with <italic>CDKN2A</italic> deletions transcriptionally resembled both mouse and human HCC harboring <italic>KMT2C</italic> alterations (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref>) but not those harboring <italic>RB1</italic> loss (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B</xref>), even though the tumor suppressor RB1 is regulated by CDKN2A/p16<sup>INK4A</sup> and their genomic alterations exhibit mutual exclusivity in multiple cancer types (<xref ref-type="bibr" rid="bib36">Knudsen et al., 2020</xref>). While we cannot rule out the possibility that other factors drive these associations, our results support a biologically meaningful relationship between MLL3 and CDKN2A.</p></sec><sec id="s2-5"><title><italic>Cdkn2a</italic> locus is a genomic and transcriptional target of MLL3 in liver cancer</title><p>To explore the relationship between MLL3 and <italic>Cdkn2a</italic> locus in more detail, we tested whether genes encoded by <italic>Cdkn2a</italic> were direct targets of MLL3-regulated transcription. Indeed, <italic>Cdkn2a</italic> is a cluster 1 locus that, in <italic>Myc</italic>; sg<italic>Kmt2c</italic> cancer cells, displays significant reduction in (1) expression, (2) H3K4me1/3 and H3K27ac levels, and (3) MLL3 binding at the <italic>Cdkn2a</italic> promoter compared with <italic>Myc</italic>; sg<italic>Trp53</italic> cells (<xref ref-type="fig" rid="fig2">Figure 2C–D</xref>, <xref ref-type="fig" rid="fig4">Figure 4A</xref>). Of note, MLL3 binding peaks were also observed within the gene body of <italic>Cdkn2a</italic>. The differential expression of Ink4a and Arf was confirmed by qPCR, immunoblotting, and ChIP-qPCR analyses on multiple <italic>Myc</italic>; sg<italic>Kmt2c</italic> and <italic>Myc</italic>; sg<italic>Trp53</italic> liver cancer lines (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A, B</xref>). These results imply that <italic>Cdkn2a</italic> locus is a genomic and transcriptional target of MLL3 in liver cancer cells.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title><italic>CDKN2A</italic> locus is a genomic and transcriptional target of MLL3 in liver cancer.</title><p>(<bold>A</bold>) Genome browser tracks for MLL3 and H3K4me1 chromatin immunoprecipitation-sequencing (ChIP-Seq) in <italic>Myc;</italic> sg<italic>Trp53</italic> (red) and <italic>Myc;</italic> sg<italic>Kmt2c</italic> (blue) hepatocellular carcinoma (HCC) cell lines at the <italic>Cdkn2a</italic> locus. (<bold>B</bold>) qPCR analysis for mRNA expression of Ink4a and Arf from three independent <italic>Myc;</italic> sg<italic>Kmt2c</italic> and <italic>Myc;</italic> sg<italic>Trp53</italic> HCC lines (n=3 cell lines each genotype). Values are shown as mean ± SD. ***=p&lt;0.001 (unpaired two-tailed t-test). (<bold>C</bold>) Schematic for CRISPR activation (CRISPRa) system of nuclease-dead Cas9 (dCas9) and VP64-p65-Rta (VPR) guided by sg<italic>KMT2C</italic> to activate <italic>KMT2C</italic> expression in human HLE HCC cell line. (<bold>D</bold>) qPCR analysis for mRNA expression of <italic>KMT2C</italic> in HLE cells with sg<italic>GFP</italic> (control) or two different CRISPRa single guide RNAs (sgRNAs) targeting <italic>KMT2C</italic> (n=4 cell lines each genotype). Each data point represents the average of technical duplicates. Data are shown as mean ± SEM. ***=p&lt;0.001 (one-way ANOVA followed by post-hoc t-tests). (<bold>E</bold>) Genome browser tracks for MLL3 ChIP-Seq at the <italic>CDKN2A</italic> locus in HLE cells with sg<italic>GFP</italic> (control, black) or sg<italic>Kmt2c</italic>.1 (blue). (<bold>F and G</bold>) qPCR analysis for mRNA expression of (<bold>F</bold>) INK4A and (<bold>G</bold>) ARF in HLE cells with sg<italic>GFP</italic> (control) or sg<italic>KMT2C</italic> (n=4). Each data point represents the average of technical duplicates. Data are shown as mean ± SEM. ***=p&lt;0.001 (one-way ANOVA followed by post-hoc t-tests).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80854-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>MLL3 directly regulates <italic>Cdkn2a</italic> expression in liver cancer cells.</title><p>(<bold>A</bold>) Immunoblots for p16<sup>Ink4a</sup> and p19<sup>Arf</sup> proteins in three independent <italic>Myc;</italic> sg<italic>Kmt2c</italic> and <italic>Myc;</italic> sg<italic>Trp53</italic> HCC lines. β-actin was used as loading control. (<bold>B</bold>) Chromatin immunoprecipitation (ChIP)-qPCR validation of H3K4me3 signals at Arf and Ink4a promoters. Values are mean ± SD from three independent <italic>Myc</italic>; sg<italic>Kmt2c;</italic> and <italic>Myc</italic>; sg<italic>Trp53</italic> liver tumor-derived cell lines. *=p&lt;0.05 (unpaired two-tailed t-test). (<bold>C</bold>) Western blot analysis of p16<sup>Ink4a</sup> and p19<sup>Arf</sup> proteins in three independent <italic>Myc</italic>; sg<italic>Trp53</italic> and <italic>Myc</italic>; sg<italic>Kmt2c</italic> cell lines expressing either a p53 shRNA (sh<italic>Trp53</italic>) or a control shRNA (sh<italic>Ren</italic>). (<bold>D</bold>) Western blot analysis of p19<sup>Arf</sup> in <italic>Myc</italic>; sg<italic>Trp53</italic> cell lines infected with two independent <italic>Kmt2c</italic> single guide RNAs (sgRNAs; sg<italic>Kmt2c</italic>.1, sg<italic>Kmt2c</italic>.2) or an empty vector (EV) control. (<bold>E</bold>) Western blot analysis of Axin1 in <italic>Myc</italic>; sg<italic>Axin1</italic> and <italic>Myc</italic>; sg<italic>Trp53</italic> cell lines. (<bold>F</bold>) qPCR analysis of <italic>Kmt2c</italic> and <italic>Cdkn2a</italic> transcripts in <italic>Myc</italic>; sg<italic>Axin1</italic> cell lines expressing two independent <italic>Kmt2c</italic> shRNAs or a control shRNA. Values are mean ± SD from experimental triplicates. For all western blots, β-actin was used as loading control. (<bold>G</bold>) Genome browser tracks for MLL3 ChIP-sequencing (ChIP-Seq) in <italic>Myc;</italic> sg<italic>Kmt2c</italic> (blue), <italic>Myc;</italic> sg<italic>Axin1</italic> (green), and <italic>Myc;</italic> sg<italic>Trp53</italic> (red) HCC cell lines at the <italic>Cdkn2a</italic> locus.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A,C,D,E</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-80854-fig4-figsupp1-data1-v2.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80854-fig4-figsupp1-v2.tif"/></fig></fig-group><p>Since the <italic>Myc</italic>; sg<italic>Trp53</italic> and <italic>Myc</italic>; sg<italic>Kmt2c</italic> cells we studied above are not isogenic, we performed a series of additional experiments to demonstrate a direct transcriptional effect of MLL3 on the <italic>Cdkn2a</italic> locus. Because p53 inactivation can lead to compensatory increases in Ink4a and Arf expression (<xref ref-type="bibr" rid="bib62">Stott et al., 1998</xref>), representing an alternative possibility accounting for the observed difference of <italic>Cdkn2a</italic> expression in sg<italic>Trp53</italic> vs sg<italic>Kmt2c</italic> cells. However, <italic>p53</italic> suppression in sg<italic>Kmt2c</italic> cells produced only a subtle and inconsistent effect on the expression of Ink4a and Arf, whereas <italic>Kmt2c</italic> suppression in sg<italic>Trp53</italic> cells consistently attenuated p16<sup>Ink4a</sup> and p19<sup>Arf</sup> protein levels (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C, D</xref>). As another means of ruling out the p53 pathway as an explanation for altered <italic>Cdkn2a</italic> expression in <italic>Myc</italic>; sg<italic>Kmt2c</italic> cells, we tested the ability of MLL3 to regulate <italic>Cdkn2a</italic> transcripts in an orthogonal liver cancer model driven by Myc and inactivation of Axin1, which is a well-defined tumor suppressor that negatively regulates β-catenin activity in HCC (<xref ref-type="bibr" rid="bib54">Satoh et al., 2000</xref>). Liver cancer cells produced by hydrodynamic delivery of the <italic>Myc</italic> transposon vector and <italic>Axin1</italic> sgRNAs displayed reduced Ink4a and Arf expression upon <italic>Kmt2c</italic> knockdown without targeting p53 (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E,F</xref>). Importantly, MLL3 binding peaks at the <italic>Cdkn2a</italic> locus were also detected in <italic>Myc</italic>; sg<italic>Axin1</italic> liver cancer cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1G</xref>), suggesting that <italic>Cdkn2a</italic> transcription is directly regulated by MLL3 rather than an indirect outcome of p53 loss. These data imply that MLL3 supports a chromatin environment at the <italic>Cdkn2a</italic> locus that facilitates the transcription of both Ink4a and Arf and raises the possibility that these factors contribute to the tumor suppressor activity of MLL3 in liver cancer.</p><p>We next set out to determine whether MLL3 binding is sufficient to induce transcriptional activation of the <italic>CDKN2A</italic> locus and, in doing so, extend our analysis to human liver cancer cells. As the <italic>KMT2C</italic> transcript is too large (14,733 bp) for cDNA transduction, we turned to the CRISPR activation (CRISPRa) system (<xref ref-type="bibr" rid="bib11">Chavez et al., 2015</xref>) in a human hepatocellular carcinoma cell line (HLE). Following stable integration of the nuclease dead Cas9 fused to the VP64-p65-Rta (VPR) transcriptional activator, cells were transduced with two orthogonal sgRNAs targeting the human <italic>KMT2C</italic> promoter (or, as control, transduced with sgRNA against GFP; <xref ref-type="fig" rid="fig4">Figure 4C</xref>). Cells expressing the <italic>KMT2C</italic> sgRNAs showed a marked and specific increase in the expression of endogenous <italic>KMT2C</italic>, but not of <italic>KMT2D</italic> or <italic>TP53</italic> (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A, B</xref>), which was accompanied by an increase in MLL3 binding to the <italic>CDKN2A</italic> locus (<xref ref-type="fig" rid="fig4">Figure 4E</xref>) and transcriptional upregulation of both <italic>CDKN2A</italic> transcripts (<xref ref-type="fig" rid="fig4">Figure 4F and G</xref>). Therefore, MLL3 directly binds and co-activates transcription of the <italic>CDKN2A</italic> locus in human liver cancer cells.</p></sec><sec id="s2-6"><title>MLL3 mediates oncogene-induced apoptosis in a <italic>Cdkn2a</italic>-dependent manner</title><p>The above results raise the possibility that the <italic>Cdkn2a</italic> products, INK4A and ARF, may contribute to the tumor suppressive activity of MLL3. In this regard, <italic>Myc</italic> overexpression in primary cells (mouse embryonic fibroblasts; MEFs) often triggers apoptosis (<xref ref-type="bibr" rid="bib22">Evan et al., 1992</xref>), and this in turn limits tumorigenesis in a manner that is dependent on <italic>Cdkn2a</italic> (<xref ref-type="bibr" rid="bib76">Zindy et al., 1998</xref>). This pathway also suppresses liver tumorigenesis since concomitant disruption of Ink4a and Arf using CRISPR, or germline deletion of Arf alone, cooperated with <italic>Myc</italic> overexpression to rapidly promote tumor development (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>). Similarly, <italic>Kmt2c</italic> suppression also attenuated MYC-induced apoptosis, as shown by tumor histology and apoptosis by TUNEL assay (<xref ref-type="bibr" rid="bib46">Negoescu et al., 1997</xref>), 5 days after hydrodynamic delivery of transposon vectors encoding <italic>Myc</italic> together with GFP-linked shRNAs targeting <italic>Kmt2c</italic> (or <italic>Renilla</italic> luciferase as a control; <xref ref-type="fig" rid="fig5">Figure 5A and B</xref>). This difference in apoptosis correlated with an increase in retention of GFP-sh<italic>Kmt2c</italic> expressing cells 10 days after injection (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D, E</xref>). Altogether, these results show that <italic>Kmt2c</italic> suppression impairs <italic>Myc</italic>-induced apoptosis in vivo in a manner that is reminiscent of the anti-apoptotic effects of <italic>Cdkn2a</italic> loss in the context of aberrant <italic>Myc</italic> activation (<xref ref-type="bibr" rid="bib21">Eischen et al., 1999</xref>; <xref ref-type="bibr" rid="bib33">Jacobs et al., 1999</xref>; <xref ref-type="bibr" rid="bib56">Schmitt et al., 1999</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>MLL3 mediates oncogene-induced apoptosis in a <italic>Cdkn2a</italic>-dependent manner.</title><p>(<bold>A</bold>) Representative images of TUNEL-positive nuclei (red staining) in murine livers 5 days after hydrodynamic injection of the indicated vector combinations. DAPI(4′,6-diamidino-2-phenylindole) was used to visualize nuclei. (<bold>B</bold>) Quantification of TUNEL-positive nuclei in mouse livers 5 days after hydrodynamic tail vein injection (HTVI) of the indicated vector combinations. Data points represent the number of TUNEL-positive cells in five different high-power fields in three independent murine livers per group. ***=p&lt;0.001 (one-way ANOVA followed by post hoc t-tests). (<bold>C</bold>) Chromatin immunoprecipitation (ChIP)-qPCR analysis for H3K4me3 signals at Arf and Ink4a promoters 4 days after doxycycline (dox) withdrawal in <italic>Myc</italic>-rtTA3; TRE-sh<italic>Kmt2c</italic> cells. Values are mean ± SD from technical replicates (n=3), and the experiments were conducted in two independent liver progenitor cell (LPC) lines with different sh<italic>Kmt2c</italic>. (<bold>D</bold>) qPCR analysis for mRNA expression of Arf and Ink4a 4 days after dox withdrawal in two independent LPC lines with different sh<italic>Kmt2c</italic>. Values are mean ± SD from technical replicates (n=3). ***=p&lt;0.001 and **=p&lt;0.01 (unpaired two-tailed t-test). (<bold>E</bold>) Representative images of colony formation assay of the indicated cell lines 5 days after dox withdrawal. (<bold>F</bold>) Quantification of colony formation assay. Values are mean ± SD of three independent experiments with two independent LPC lines. *=p&lt;0.05 (unpaired two-tailed t-test). (<bold>G</bold>) Time course analysis of Draq7-positive (dead or permeabilized) cells as a fraction of Venus-positive, <italic>Myc</italic>-rtTA3; TRE-sh<italic>Kmt2c</italic> cells expressing constitutive shRNAs targeting both Ink4a and Arf (sh<italic>Cdkn2a</italic>) or <italic>Renilla</italic> luciferase (sh<italic>Ren</italic>) off and on dox. Values represent mean ± SEM of triplicate wells of each genotype at each timepoint of two independently derived LPC lines, infected with either sh<italic>Ren</italic> or sh<italic>Cdkn2a</italic>. *=p&lt;0.05 (unpaired two-tailed t-test of final average percentage Draq7<sup>+</sup>/GFP<sup>+</sup>). NS, not significant (p&gt;0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80854-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title><italic>Kmt2c</italic> suppression reduces cell clearance upon enforced <italic>Myc</italic> expression in vivo.</title><p>(<bold>A–B</bold>) qPCR analysis for mRNA expression of <italic>KMT2D and TP53</italic> in human HLE cells with sg<italic>GFP</italic> (control) or CRISPRa sg<italic>KMT2C</italic> (n=4). Each data point represents the average of technical duplicates. Data are shown as mean ± SEM. (<bold>C</bold>) Survival curve of wild-type mice injected with <italic>Myc</italic> transposon and pX330 expressing single guide RNAs (sgRNAs) targeting <italic>Cdkn2a</italic> (<italic>Myc;</italic> sg<italic>Cdkn2a</italic>, n=5), or Arf-null mice injected with <italic>Myc</italic> vectors (<italic>Myc</italic>; Arf-null, n=5). Wild-type mice injected with <italic>Myc;</italic> sg<italic>GFP</italic> (n=3) served as a control. (<bold>D</bold>) Representative images of GFP-expressing cells detected by immunohistochemistry in murine livers 10 days after hydrodynamic injection of vectors enforcing stable expression of <italic>Myc</italic> and GFP-linked, constitutive shRNAs targeting <italic>Kmt2c</italic> or <italic>Renilla</italic> luciferase. (<bold>E</bold>) Quantification of GFP-positive cells in murine livers 10 days after hydrodynamic injection of the indicated vector combinations. Each data point represents GFP-positive cells in one of 10 different high-power fields (HPFs) in one of three independent murine livers.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80854-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Endogenous <italic>Kmt2c</italic> restoration triggers apoptosis and is accompanied by increased <italic>Cdkn2a</italic> expression.</title><p>(<bold>A</bold>) Schematic for generating immortalized liver progenitor cell (LPC) lines from ED13 liver progenitor cells. (<bold>B</bold>) Western blot analysis of p16<sup>Ink4a</sup>, p19<sup>Arf</sup>, and MYC in wild-type LPCs 2 days after <italic>Myc</italic> transduction. (<bold>C</bold>) <italic>Kmt2c</italic> mRNA expression before (on) and after (off) <italic>Kmt2c</italic> restoration in LPCs expressing with two independent tet-regulated <italic>Kmt2c</italic> shRNAs. Values are mean ± SD from technical replicates (n=3). ***=p&lt;0.001 (unpaired two-tailed t-test). (<bold>D</bold>) Representative images of colony formation assay of LPCs 4 days after <italic>Kmt2c</italic> restoration. (<bold>E</bold>) Annexin-V labeling in <italic>Myc</italic>-rtTA3; TRE-sh<italic>Kmt2c</italic> cells grown for 3 days with or without doxycycline (dox). Data are shown as mean ± SD of wells analyzed in triplicate. ***=p&lt;0.001 (unpaired two-tailed t-test). (<bold>F</bold>) Western blot analysis of p16<sup>Ink4a</sup> and p19<sup>Arf</sup> 4 days after dox withdrawal in <italic>Myc</italic>-rtTA3; TRE-sh<italic>Kmt2c</italic> cells. (<bold>G</bold>) Western blot analysis of p16<sup>Ink4a</sup> and p19<sup>Arf</sup> proteins in <italic>Kmt2c</italic> -restored LPCs (two independent shRNAs targeting <italic>Kmt2c</italic>) with constitutively expressed control shRNAs (sh<italic>Ren</italic>) or <italic>Cdkn2a</italic>-targeting shRNAs (sh<italic>Cdkn2a</italic>). For all western blots, β-actin was used as loading control.</p><p><supplementary-material id="fig5s2sdata1"><label>Figure 5—figure supplement 2—source data 1.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2B,F,G</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-80854-fig5-figsupp2-data1-v2.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80854-fig5-figsupp2-v2.tif"/></fig></fig-group><p>To model the interaction between <italic>Myc</italic> overexpression, MLL3 function, and <italic>Cdkn2a</italic> regulation, we transduced liver progenitor cells (LPCs) with retroviral vectors encoding <italic>Myc</italic> linked to a reverse tetracycline transactivator (rtTA3), together with doxycycline (dox)-inducible <italic>Kmt2c</italic> shRNAs to enable reversible <italic>Kmt2c</italic> silencing (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A</xref>). Infection of LPCs with <italic>Myc</italic> in the presence of MLL3 (i.e. cells infected with <italic>Myc</italic>-rtTA3 and a dox-inducible shRNA targeting <italic>Renilla</italic> luciferase) acutely activated INK4A and ARF expression (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2B</xref>), and these cells could not be maintained in culture. Phenocopying the ability of <italic>Myc</italic> and <italic>Kmt2c</italic> suppression to transform liver cells in vivo, combined <italic>Myc</italic> and sh<italic>Kmt2c</italic> expression facilitated the persistent growth of cells maintained on Dox (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2C,D</xref>). By contrast, dox withdrawal induced <italic>Kmt2c</italic> mRNA expression and H3K4me3 deposition at the <italic>Cdkn2a</italic> promoters, ultimately leading to elevations in Arf and Ink4a mRNA and protein (<xref ref-type="fig" rid="fig5">Figure 5C and D</xref>), reduced colony formation, and increased apoptosis (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2D–F</xref>). Furthermore, constitutive shRNA-mediated knockdown of Arf and Ink4a through targeting of the shared exon 2 (sh<italic>Cdkn2a</italic>) significantly rescued colony-forming capacity and prevented cell death following <italic>Kmt2c</italic> restoration as determined by time-lapse microscopy of cells cultured with a fluorescent dye that stains dead cells (<xref ref-type="fig" rid="fig5">Figure 5E–G</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2G</xref>). These data support a model whereby a prominent tumor suppressive output of MLL3 in liver cancer involves direct upregulation of <italic>Cdkn2a</italic> that, when impaired, attenuates the MYC-induced apoptotic program and permits tumor progression.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Our study combined genetic, epigenomic, and animal modeling approaches to identify <italic>Cdkn2a</italic> as an important regulatory target of MLL3 in both mouse and human liver cancers. Our results support a model whereby oncogenic stress, herein produced by MYC, leads to an increase in the binding of MLL3 to the <italic>CDKN2A</italic> locus, an event that is associated with the accumulation of histone marks linked to the biochemical activity of MLL3-containing complexes and conducive to gene activation (<xref ref-type="fig" rid="fig6">Figure 6</xref>). Accordingly, these events are accompanied by transcriptional upregulation of two key <italic>Cdkn2a</italic> gene products, Ink4a and Arf. Moreover, suppression of <italic>Kmt2c</italic> phenocopies the effects of <italic>Cdkn2a</italic> inactivation in abrogating MYC-induced apoptosis. Conversely, suppression of <italic>Cdkn2a</italic> diminishes the anti-proliferative effects of <italic>Kmt2c</italic> restoration. As such, our results establish a conserved epistatic relationship between the chromatin modifier MLL3 and a well-characterized tumor suppressor network.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Model of MLL3 as a tumor suppressor in liver cancer.</title><p>MLL3 restricts MYC-induced liver tumorigenesis by directly activating the <italic>Cdkn2a</italic> locus to mediate tumor cell apoptosis.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80854-fig6-v2.tif"/></fig><p>The epistatic relationship described above might be expected to lead to mutual exclusivity of <italic>KMT2C</italic> and <italic>CDKN2A</italic> alterations; however, we did not observe significant mutual exclusivity in liver cancer, which is likely due to insufficient samples sizes needed to obtain statistical power. Alternatively, other functionally important components linked to the <italic>CDKN2A</italic> locus could produce <italic>CDKN2A</italic>-independent forces that drive selection for chromosome 9p deletions, including type I interferon genes, <italic>CDKN2B</italic>, and <italic>MTAP</italic> (<xref ref-type="bibr" rid="bib5">Barriga et al., 2022</xref>). Alternatively, mutual exclusivity between <italic>KMT2C</italic> and <italic>CDKN2A</italic> alterations would be expected only under circumstances where <italic>CDKN2A</italic> action is the most dominant MLL3 effector. Indeed, it seems likely that multiple downstream genes, including factors involved in interactions with stromal and immune populations, contribute to MLL3-driven tumor suppression, and their relative importance may vary between cell and tissue types. Such a variable output in cancer-relevant gene regulation has been noted for other chromatin regulators that, at the extreme, serve as pro-oncogenic factors in some contexts and tumor suppressors in others (<xref ref-type="bibr" rid="bib23">Fountain et al., 1992</xref>; <xref ref-type="bibr" rid="bib55">Schmid et al., 2000</xref>; <xref ref-type="bibr" rid="bib64">Sun et al., 2017</xref>; <xref ref-type="bibr" rid="bib72">Xia et al., 2021</xref>). Furthermore, our observation that <italic>Kmt2c</italic> deficiency cooperated with MYC but not CTNNB1 to drive HCC highlights such context specificity and is in line with recent findings that chromatin context could favor particular oncogenic alterations over others (<xref ref-type="bibr" rid="bib71">Weiss et al., 2022</xref>).</p><p>UTX (KDM6A), MLL3 (KMT2C), and MLL4 (KMT2D), the core catalytic components of the COMPASS-like complex, are all considered tumor suppressors, with frequent loss-of-function genomic alterations found in a broad spectrum of human cancers (<xref ref-type="bibr" rid="bib51">Revia et al., 2022</xref>; <xref ref-type="bibr" rid="bib65">Sze and Shilatifard, 2016</xref>). While each of these components regulates redundant sets of genes (<xref ref-type="bibr" rid="bib31">Hu et al., 2013</xref>; <xref ref-type="bibr" rid="bib40">Lee et al., 2009</xref>), they may exert their tumor suppressive functions through different mechanisms. In liver and pancreas cancer models, UTX can control the expression of negative regulators of mTOR such as <italic>DEPTOR</italic>, and its disruption prevents their transcription and facilitates tumorigenesis through increased mTORC1 activity (<xref ref-type="bibr" rid="bib51">Revia et al., 2022</xref>). Additionally, while the mechanisms of MLL4 activity have not been examined in liver cancer, studies suggest that MLL4 suppresses skin carcinogenesis by promoting lineage stability and ferroptosis independently of MLL3 (<xref ref-type="bibr" rid="bib20">Egolf et al., 2021</xref>). Our study demonstrates that MLL3 is both necessary and sufficient for efficient transcriptional activation of the <italic>CDKN2A</italic> locus that drives oncogene-induced apoptosis. The molecular basis for this heterogeneity in effector output remains to be determined, but it seems likely that different subsets of target genes are preferentially disabled by haploinsufficiency of individual components and/or subject to compensation by the remaining COMPASS complex activities. Systematic studies comparing the binding, histone modifications, and transcriptional output of cells across a spectrum of allelic configurations of COMPASS complex factors will be needed to achieve a more holistic understanding of their functions and interactions in different contexts.</p><p>The most well-established role for MLL3/4-UTX-containing complexes is the control of H3K4 monomethylation at enhancers during development (<xref ref-type="bibr" rid="bib28">Herz et al., 2010</xref>; <xref ref-type="bibr" rid="bib31">Hu et al., 2013</xref>). While our ChIP-Seq studies also revealed binding of MLL3/4 to enhancers in liver tumor cells, an even larger fraction of genes—including <italic>Cdkn2a</italic>—showed MLL3/4 chromatin enrichment at gene promoters, and indeed, transcription of this class of genes was most affected by <italic>Kmt2c</italic> disruption. Interestingly, <italic>Kmt2c</italic> suppression preferentially limited the MLL3/4 enrichment at promoters and shifted residual complex binding toward intergenic regions. Such dynamic regulation of distinct cis-acting elements by the MLL3/4 complex has also been observed in other contexts (<xref ref-type="bibr" rid="bib13">Cheng et al., 2014</xref>; <xref ref-type="bibr" rid="bib61">Soto-Feliciano et al., 2023</xref>), where the non-canonical binding of MLL3/4 at promoters is a recurrent tumor suppressive mechanism in cancer cells. MLL3/4 has also been observed to bind within the exons and introns, which may enable chromatin looping of enhancers to activate gene expression (<xref ref-type="bibr" rid="bib48">Panigrahi and O’Malley, 2021</xref>). Further studies into the action and regulation of MLL3/4 complexes at promoters and gene bodies will be informative and may yield new insights into the actions of the COMPASS-like complex in cancer.</p><p>While <italic>CDKN2A</italic> showed a surprisingly dominant role in mediating the tumor-suppressive effects of the broadly acting MLL3 enzyme, there are precedents for a predominant contribution of a single gene to the functional output of chromatin-complex disruption. Indeed, polycomb repressive complexes (PRCs) broadly repress gene expression in different cell types through the coordinated action of PRC1 and PRC2 complexes that deposit and maintain repressive H3K27me3 marks on the enhancers of target genes, including <italic>CDKN2A</italic> (<xref ref-type="bibr" rid="bib8">Bracken et al., 2007</xref>; <xref ref-type="bibr" rid="bib37">Kotake et al., 2007</xref>). Despite these similarly broad effects, <italic>CDKN2A</italic> is often the most functionally relevant target of PRC-mediated repression, as genetic deletion of either the PRC1 component <italic>Bmi1</italic> or the PRC2 component <italic>Ezh2</italic>, or treatment with small molecule inhibitors of EZH2, can facilitate <italic>Cdkn2a</italic> induction in normal and tumor cells. This, in turn, triggers anti-proliferative responses that can be rescued by <italic>Cdkn2a</italic> deletion (<xref ref-type="bibr" rid="bib33">Jacobs et al., 1999</xref>; <xref ref-type="bibr" rid="bib52">Richly et al., 2011</xref>). Notably, the COMPASS-like complexes are biochemically and functionally similar to Trithorax complexes in <italic>Drosophila</italic>, which have an evolutionarily conserved antagonistic relationship with PRC1 and PRC2 that controls epigenetic memory and cell fate during development (<xref ref-type="bibr" rid="bib43">Mills, 2010</xref>; <xref ref-type="bibr" rid="bib49">Piunti and Shilatifard, 2016</xref>). Our findings suggest such antagonism extends to tumor suppression in mammalian cells, likely via regulation of <italic>Cdkn2a</italic> and other tumor suppressor genes (<xref ref-type="bibr" rid="bib61">Soto-Feliciano et al., 2023</xref>).</p><sec id="s3-1"><title>Materials availability statement</title><p>Source files of all original gels and western blots were provided for the following figures:</p><list list-type="simple"><list-item><p><xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>;</p></list-item><list-item><p><xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A, C, D, E</xref>;</p></list-item><list-item><p><xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2B, F, G</xref>.</p></list-item></list><p>RNA sequencing and ChIP-Seq data files that support the findings of this study have been deposited in the Gene Expression Omnibus under the accession code GSE85055, as well as in the Dryad digital repository (doi:10.5061/dryad.7pvmcvdwm; doi:10.5061/dryad.f1vhhmh0h). Sequences of sgRNAs, shRNAs, and primers used in this manuscript are included in the <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Animal experiments</title><p>8- to 10-week-old female C57BL/6 animals were purchased from Envigo (formerly Harlan). Each experiment was performed in mice from the same order. Arf-null animals (C57BL/6 background), originally provided by Dr. Charles Sherr, St. Jude Children’s Research Hospital, were maintained in our breeding colony. For HTVI, a sterile 0.9% NaCl solution/plasmid mix was prepared containing oncogene transposons (5 µg DNA of pT3-<italic>Myc</italic> or 10 µg pT3-<italic>Ctnnb1 N90</italic>) with either 20 µg of pX330 expressing the indicated sgRNAs or 20 µg of pT3-EF1a-GFP-miRE plasmid together with CMV-SB13 Transposase (1:5 ratio). Mice were randomly assigned to experimental groups and injected with the 0.9% NaCl solution/plasmid mix into the lateral tail vein with a total volume corresponding to 10% of body weight in 5–7 s as described before (<xref ref-type="bibr" rid="bib38">Largaespada, 2009</xref>; <xref ref-type="bibr" rid="bib45">Moon et al., 2019</xref>; <xref ref-type="bibr" rid="bib66">Tschaharganeh et al., 2014</xref>; <xref ref-type="bibr" rid="bib73">Xue et al., 2014</xref>). Injected mice were monitored for tumor formation by abdominal palpation. All animal experiments were approved by the Memorial Sloan Kettering Cancer Center (MSK) Institutional Animal Care and Use Committee (protocol 11-06-011). Animals were monitored for signs of ill health by veterinary staff at the Research Animal Resource Center at MSK, and efforts were made to minimize suffering.</p></sec><sec id="s4-2"><title>Vector constructs</title><p>The pT3-<italic>Myc</italic> vector Addgene (#92046) and pT3-EF1a-GFP-miRE plasmid were described before (<xref ref-type="bibr" rid="bib32">Huang et al., 2014</xref>). The pT3-<italic>Ctnnb1 N90</italic> vector (<xref ref-type="bibr" rid="bib67">Tward et al., 2007</xref>) was obtained from Addgene (#31785). For CRISPR/Cas9-mediated genome editing, sgRNAs were subcloned into pX330 (Addgene, #42230; <xref ref-type="bibr" rid="bib30">Hsu et al., 2013</xref>). All shRNA and sgRNA sequences are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-3"><title>Derivation of primary liver tumor cell lines</title><p>Liver tumors were resected with sterile instruments, and 10–50 mg of tumor tissue was minced and washed in sterile PBS, incubated in a mix of 1 mg/mL collagenase IV and 3 mg/mL dispase (dissolved in sterile, serum-free DMEM(Dulbecco's Modified Eagle Medium)) with gentle shaking, washed with PBS, incubated for 5 min in 0.05% (w/v) trypsin, and washed and plated in complete DMEM (10% FBS(fetal bovine serum), 1× penicillin/streptomycin) on collagen-coated plates (PurCol, Advanced Biomatrix). Primary cultures were passaged until visibly free from fibroblasts. Cell lines were authenticated on a routine basis using short tandem repeat profiling, as well as tested for mycoplasma contamination and immediately discarded upon a positive test.</p></sec><sec id="s4-4"><title>Analysis of CRISPR-directed mutations</title><p>CRISPR-mediated insertions and deletions were detected by surveyor assay as directed by the manufacturer (Transgenomic/IDT). Briefly, after overnight lysis of primary tumors and cell lines at 37°C in buffer containing 0.4 mg/mL proteinase K, 10 mM Tris, 100 mM NaCl, 10 mM EDTA, and 0.5% SDS, pH 8.0, genomic DNA was extracted by isopropanol precipitation. ~250–500 bp regions flanking predicted CRISPR cleavage sites were PCR amplified with Herculase II taq polymerase, column purified (Qiagen), heated to 95°C, and slowly cooled to promote annealing of heteroduplexes. Following treatment with Surveyor nuclease, products were analyzed by electrophoresis on a 2% polyacrylamide gel. Primers used for surveyor assay are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. Amplified PCR products were separately gel purified and ligated into blunt-end digested pBlueScript (Stratagene). DNA from 48 transformed colonies was analyzed by Sanger sequencing using a T7 primer.</p></sec><sec id="s4-5"><title>CRISPR activation</title><p>Human HCC cell line HLE, purchased from JCRB Cell Bank (JCRB0404), was transduced by the lentivirus expressing nuclease-dead Cas9 (dCas9) fused with VPR (<xref ref-type="bibr" rid="bib11">Chavez et al., 2015</xref>) and sgRNAs against <italic>KMT2C</italic> (sequence in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) to generate stable MLL3 CRISPRa HLE line by puromycin selection.</p></sec><sec id="s4-6"><title>Generation and modification of primary cells</title><p>LPCs from E13.5–15.5 C57BL/6 embryos were isolated and grown in hepatocyte growth media (HGM) as previously described (<xref ref-type="bibr" rid="bib74">Zender et al., 2005</xref>). To simultaneously overexpress <italic>Myc</italic> and conditionally suppress <italic>Kmt2c</italic>, LPCs were co-infected with a retroviral construct constitutively expressing both <italic>Myc</italic> and a reverse tet-transactivator (rtTA) (MSCV-<italic>Myc</italic>-IRES-rtTA) along with retroviral TRMPV vectors (MSCV-TRE-dsRed-miR30/shRNA-PGK-Venus-IRES-NeoR) (<xref ref-type="bibr" rid="bib77">Zuber et al., 2011</xref>) expressing ds-Red linked, teint-responsive shRNAs targeting <italic>Kmt2c</italic> cloned into an optimized mir-30 context (‘mir-E,’ TRPMVe; <xref ref-type="bibr" rid="bib77">Zuber et al., 2011</xref>). For selection of infected cells and sustained sh<italic>Kmt2c</italic> expression, cells were maintained in HGM with neomycin (1 mg/mL) and dox (1 µg/mL) starting 2 days after infection. To introduce constitutively expressed shRNAs in the setting of inducible sh<italic>Kmt2c</italic>, retroviral MLPe vectors (MSCV-LTR-mir-E-PGK-Puro-IRES-GFP; <xref ref-type="bibr" rid="bib17">Dickins et al., 2005</xref>). GFP-linked shRNAs targeting either <italic>Cdkn2a</italic> or <italic>Renilla</italic> luciferase (as control) were co-infected with MSCV-<italic>Myc</italic>-IRES-rtTa and TRMPVe-sh<italic>Kmt2c</italic>. Triple-infected cells were maintained in media with neomycin, puromycin (2 µg/mL), and dox 2 days post infection. Infected continuously proliferating cells were transitioned to growth in complete DMEM and maintained on collagen-coated plates.</p></sec><sec id="s4-7"><title>Colony assays</title><p>For measurement of cell proliferation, 5000 transduced and selected LPCs or MEFs were plated in triplicate in 6-well plates. Tetracycline-inducible sh<italic>Kmt2c</italic>–expressing LPCs were grown in the presence or absence of dox, and after 5 days, cells were fixed with formalin and methanol and stained with 0.05% crystal violet. MEFs were fixed after 6 days with formalin and methanol and stained with 0.05% crystal violet.</p></sec><sec id="s4-8"><title>Apoptosis assays</title><p>Apoptosis was measured in LPCs via Annexin V staining according to the manufacturer’s instructions (eBiosciences, Annexin-V APC). 25,000 cells were grown with and without dox for 3 days, trypsinized, washed with Annexin-V binding buffer, and ~100,000 cells were incubated with Annexin-V APC and analyzed on an LSRII flow cytometer (BD).</p></sec><sec id="s4-9"><title>Live imaging</title><p>Imaging was performed on LPCs immortalized by linked overexpression of <italic>Myc</italic> and two independent, inducible <italic>Kmt2c</italic> shRNAs constitutively expressing shRNAs targeting <italic>Renilla</italic> luciferase or <italic>Cdkn2a</italic> (generated as detailed above). 1000 cells were plated on collagen-coated, 96 well, clear bottom imaging plates in media supplemented with 300 nM Draq7 (Invitrogen) with and without dox, in triplicate by genotype. 18 hr after plating cells, Venus (marking all plated cells) and Draq7 fluorescence was collected in two, 10× fields of each well every 15 min for 41 hr using an automated, high content microscope (InCell 6000, General Electric).</p></sec><sec id="s4-10"><title>Chromatin immunoprecipitation</title><p>Histone ChIP was performed as previously described (<xref ref-type="bibr" rid="bib39">Lee et al., 2006</xref>). Briefly, cell samples were cross-linked in 1% formaldehyde for 10 min, and the reaction was stopped by addition of glycine to 125 mM final concentration. Fixed cells were lysed in SDS lysis buffer, and the chromatin was fragmented by sonication (Covaris). Sheared chromatin was incubated with antibodies (final concentration 10 µg/mL) against H3K4me3 (Abcam, ab8580, Lot:GR164706-1), H3K27ac (Abcam, ab4729, Lot:GR200563-1), or H3K4me1 (Abcam; ab8895, Lot:GR114265-2) or with normal rabbit IgG (Abcam, ab46540) at 4°C for overnight. Antibodies were recovered by binding to protein A/G agarose (Millipore), and the eluted DNA fragments were used directly for qPCR or subjected to high-throughput sequencing (ChIP-Seq) using a HiSeq 2000 platform (Illumina). High-throughput reads were aligned to mouse genome assembly NCBI37/mm9 as previously described (<xref ref-type="bibr" rid="bib4">Barradas et al., 2009</xref>). Reads that aligned to multiple loci in the mouse genome were discarded. The ChIP-Seq signal for each gene was quantified as total number of reads per million in the region 2 kb upstream to 2 kb downstream of the transcription start site (TSS). Primers used for ChIP-qPCR of mouse <italic>Cdkn2a</italic> promoter (<xref ref-type="bibr" rid="bib4">Barradas et al., 2009</xref>) are listed in Table S1.</p><p>The complete dataset is available at NCBI Gene Expression Omnibus (GSE85055), as well as the Dryad digital repository (doi:10.5061/dryad.7pvmcvdwm).</p><p>For the MLL3 ChIP-Seq, the following protocol was used. Cross-linking ChIP in mouse and human HCC cells was performed with 10–20×10<sup>7</sup> cells per immunoprecipitation. Cells were collected, washed once with ice-cold PBS, and flash-frozen. Cells were resuspended in ice-cold PBS and cross-linked using 1% paraformaldehyde (PFA; Electron Microscopy Sciences) for 5 min at room temperature with gentle rotation. Unreacted PFA was quenched with glycine (final concentration 125 mM) for 5 min at room temperature with gentle rotation. Cells were washed once with ice-cold PBS and pelleted by centrifugation (800 <italic>g</italic> for 5 min). To obtain a soluble chromatin extract, cells were resuspended in 1 mL of LB1 (50 mM HEPES pH 7.5, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100, and 1× complete protease inhibitor cocktail) and incubated at 4°C for 10 min while rotating. Samples were centrifuged (1400 <italic>g</italic> for 5 min), resuspended in 1 mL of LB2 (10 mM Tris-HCl pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, and 1× complete protease inhibitor cocktail), and incubated at 4°C for 10 min while rotating. Finally, samples were centrifuged (1400 <italic>g</italic> for 5 min) and resuspended in 1 mL of LB3 (10 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% sodium deoxycholate, 0.5% N-lauroylsarcosine, and 1× complete protease inhibitor cocktail). Samples were homogenized by passing seven to eight times through a 28-gauge needle, then Triton X-100 was added to a final concentration of 1%. Chromatin extracts were sonicated for 14 min using a Covaris E220 focused ultrasonicator. Lysates were centrifuged at 20,000 <italic>g</italic> for 10 min at 4°C, and 5% of the supernatant was saved as input DNA. Beads were prepared by incubating them in 0.5% BSA in PBS and antibodies overnight (100 μL of Dynabeads Protein A or Protein G [Invitrogen] plus 20 μL of antibody). The antibody was anti-MLL3/4, which was kindly provided by the Wysocka laboratory (<xref ref-type="bibr" rid="bib19">Dorighi et al., 2017</xref>). Antibody-beads mixes were washed with 0.5% BSA in PBS and then added to the lysates overnight while rotating at 4°C. Beads were then washed six times with RIPA buffer (50 mM HEPES pH 7.5, 500 mM LiCl, 1 mM EDTA, 0.7% sodium-deoxycholate, and 1% NP-40) and once with TE-NaCl Buffer (10 mM Tris-HCl pH 8.0, 50 mM NaCl, and 1 mM EDTA). Chromatin was eluted from beads in Elution buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA, and 1% SDS) by incubating at 65°C for 30 min while shaking, supernatant was removed by centrifugation, and crosslinking was reversed by further incubating chromatin overnight at 65°C. The eluted chromatin was then treated with RNase A (10 mg/mL) for 1 hr at 37°C and with proteinase K (Roche) for 2 hr at 55°C. DNA was purified by using phenol-chloroform extraction followed with ethanol precipitation. The NEBNext Ultra II DNA Library Prep kit was used to prepare samples for sequencing on an Illumina NextSeq500 (75 bp read length, single-end, or 37 bp read length, and paired-end).</p><p>The complete dataset for MLL3 ChIP-Seq is available at the Dryad digital repository (doi:10.5061/dryad.f1vhhmh0h).</p></sec><sec id="s4-11"><title>Immunoblotting</title><p>Cell pellets were lysed in Laemmli buffer (100 mM Tris-HCl pH 6.8, 5% glycerol, 2% SDS, and 5% 2-mercaptoethanol). Equal amounts of protein were separated on 12% SDS–polyacrylamide gels and transferred to PVDF(polyvinylidene difluoride) membranes (90 V, 75 min). β-actin was used as a control to ensure equal loading, and images were analyzed using the AlphaView software (ProteinSimple). Immunoblotting was performed using antibodies for MYC (1:1000, Abcam, ab32072), p53 (1:500, Leica Biosystems, NCL-p53-505), p19 (1:250, Santa Cruz Biotechnology, sc-32748), p16 (1:250, Santa Cruz Biotechnology, sc-1207), Axin1 (1:1000, Cell Signaling, #2074), and β-actin (1:10000, Sigma-Aldrich, clone AC-15). Source files of all western blots were provided for <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>.</p></sec><sec id="s4-12"><title>Quantitative RT-PCR</title><p>Total RNA was isolated using RNeasy Mini Kit, QIAshredder Columns, and RNase-Free DNase Set (Qiagen). cDNA synthesis was performed using TaqMan Reverse Transcription Reagents (Thermo Fisher Scientific). Real-time PCR was carried out using Power SYBR Green Master Mix (Thermo Fisher Scientific) and the Life Technologies ViiA 7 machine. Transcript levels were normalized to the levels of mouse or human <italic>Actb</italic> mRNA expression and calculated using the ΔΔCt method. Each qRT-PCR was performed in triplicate using gene-specific primers (sequences listed in Table S1).</p></sec><sec id="s4-13"><title>RNA sequencing and differential expression analysis</title><p>For RNA sequencing, total RNA from three independent tumor-derived cell lines (<italic>Myc</italic>; sg<italic>Trp53</italic> and <italic>Myc</italic>; sg<italic>Kmt2c</italic>) was isolated using RNeasy Mini Kit, QIAshredder Columns and RNase-Free DNase Set (Qiagen). RNA-Seq library construction and sequencing were performed according to protocols used by the integrated genomics operation Core at MSK. 5–10 million reads were acquired per replicate sample. After removing adaptor sequences with Trimmomatic, RNA-seq reads were aligned to GRCm38.91(mm10) with STAR (<xref ref-type="bibr" rid="bib18">Dobin et al., 2013</xref>). Genome-wide transcript counting was performed by HTSeq to generate an FPKM(Fragments Per Kilobase per Million mapped fragments) matrix (<xref ref-type="bibr" rid="bib3">Anders et al., 2015</xref>). DEGs were identified by DESeq2 (v.1.8.2, package in R) and plotted in the volcano plot. The complete dataset is available at NCBI Gene Expression Omnibus (GSE85055).</p></sec><sec id="s4-14"><title>Integrative analyses of RNA-seq and MLL3 ChIP-seq</title><p>Differential peaks from ChIP-Seq data were annotated by assigning all intragenic peaks to that gene while intergenic peaks were assigned using linear genomic distance to the TSS. Genes that were coordinately regulated (fold change &gt;1.5 and adjusted p-value&lt;0.1) in MLL3 ChIP-seq and RNA-seq data were selected for the integrated analysis. Enriched pathways were scored using the enrichGO function with ‘biological process’ in the clusterProfiler R package. Redundant pathways were collapsed using the ‘simplify’ function with a cutoff of 0.7 with the p.adjust metric. Network analysis was performed using differential peaks and genes by running enrichplot::cnetplot in R with default parameters.</p></sec><sec id="s4-15"><title>Human cancer analyses</title><p>RNA sequencing data of selected samples with somatic mutations or homozygous deletions of <italic>KMT2C</italic>, <italic>CDKN2A</italic>, <italic>TP53</italic>, or <italic>RB1</italic> in the TCGA HCC dataset were downloaded from Broad Institute TCGA Genome Data Analysis Center. To obtain transcriptional signatures of HCC with genomic mutations and deletions of either <italic>KMT2C</italic>, <italic>CDKN2A</italic>, and <italic>RB1</italic>, differential gene expression analyses were performed by DESeq2 (with <italic>TP53</italic>-mutated HCCs as controls). The oncoprints of homozygous deletions and somatic mutations of <italic>KMT2C</italic>, <italic>CDKN2A</italic>, and <italic>TP53</italic>, as well as MYC gains and amplifications from human HCC datasets (<xref ref-type="bibr" rid="bib9">Cancer Genome Atlas Research Network, 2017</xref>, MSK [<xref ref-type="bibr" rid="bib27">Harding et al., 2019</xref>; <xref ref-type="bibr" rid="bib75">Zheng et al., 2018</xref>], INSERM [<xref ref-type="bibr" rid="bib58">Schulze et al., 2015</xref>], RIKEN [<xref ref-type="bibr" rid="bib24">Fujimoto et al., 2012</xref>], AMC [<xref ref-type="bibr" rid="bib1">Ahn et al., 2014</xref>], and MERCi [<xref ref-type="bibr" rid="bib47">Ng et al., 2022</xref>]) were generated by cBioPortal (<ext-link ext-link-type="uri" xlink:href="https://www.cbioportal.org">https://www.cbioportal.org</ext-link> ; <xref ref-type="bibr" rid="bib10">Cerami et al., 2012</xref>; <xref ref-type="bibr" rid="bib25">Gao et al., 2013</xref>).</p></sec><sec id="s4-16"><title>Gene set enrichment analysis</title><p>GSEA was performed using the GSEAPreranked tool for conducting GSEA of data derived from RNA-seq experiments (version 2.07) against other signatures. The metric scores (normalized enrichment scores and false discovery rate q-values) were calculated using the sign of the fold change multiplied by the inverse of the p-value (<xref ref-type="bibr" rid="bib63">Subramanian et al., 2005</xref>). Specifically, transcriptional signatures were derived based on significantly changed genes (p-adjusted&lt;0.05, absolute fold change &gt;2) from RNA-seq of mouse HCC cell lines (<italic>Myc</italic>; sg<italic>Kmt2c</italic> vs <italic>Myc</italic>; sg<italic>Trp53</italic>, n=3 each genotype), and in human HCCs with mutations in <italic>KMT2C</italic> vs <italic>TP53</italic> (p-adjusted&lt;0.05, absolute fold change &gt;2). These signatures were compared to the transcriptional comparison of TCGA human HCCs with genomic inactivation of <italic>CDKN2A</italic> vs <italic>TP53</italic>.</p></sec><sec id="s4-17"><title>Statistical analyses</title><p>Data are presented as mean ± D or SEM as specified. The statistical comparison between two groups was accomplished with the two-tailed student’s t-test or one-way ANOVA followed by post hoc t-tests among three or more groups. The analyses for co-occurrence or mutual exclusivity of mutations were performed using Fisher Exact test. Comparisons of survival curves were performed by log-rank tests. All statistical tests were performed using the Prism 8 software. All data presented in the manuscript have been replicated in independent cohorts of mice or in at least three biological replicates for in vitro experiments. On the basis of predicted effects of oncogene-tumor suppressor interaction introduced by HTVI in mice, with a power of 0.8 and p&lt;0.05, we calculated a minimum sample size of 5 mice per group. Animals within the same cage were randomly allocated into control and experimental groups, with the group assignment recorded in a master spreadsheet and unmasked only when all samples of the respective experiments were analyzed. Data collection of each experiment was detailed in the respective figures, figure legends, and methods. No data were excluded from studies in this manuscript.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>is a co founder of Chroma Therapeutics and Constellation Pharmaceuticals and a Scientific Advisory Board member of EpiCypher</p></fn><fn fn-type="COI-statement" id="conf3"><p>is an advisor for and has equity in the following biotechnology companies: ORIC Pharmaceuticals, Faeth Therapeutics, Blueprint Medicines, Geras Bio, Mirimus Inc, Senescea, and PMV Pharmaceuticals. S.W.L. also acknowledges receiving funding and research support from Agilent Technologies and Calico, for the purposes of massively parallel oligo synthesis and single-cell analytics, respectively</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con5"><p>Software, Formal analysis, Visualization, Methodology</p></fn><fn fn-type="con" id="con6"><p>Software, Formal analysis, Visualization, Methodology</p></fn><fn fn-type="con" id="con7"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Formal analysis</p></fn><fn fn-type="con" id="con9"><p>Methodology</p></fn><fn fn-type="con" id="con10"><p>Methodology</p></fn><fn fn-type="con" id="con11"><p>Methodology</p></fn><fn fn-type="con" id="con12"><p>Methodology</p></fn><fn fn-type="con" id="con13"><p>Methodology</p></fn><fn fn-type="con" id="con14"><p>Methodology</p></fn><fn fn-type="con" id="con15"><p>Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Data curation, Formal analysis, Supervision, Validation, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con17"><p>Conceptualization, Resources, Supervision, Funding acquisition, Investigation, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animal experiments were approved by the MSKCC Institutional Animal Care and Use Committee (protocol 11-06-011). Animals were monitored for signs of ill-health by veterinary staff at the Research Animal Resource Center (RARC) at MSKCC and efforts were made to minimize suffering.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Tables displaying the sequences of single guide RNA (sgRNA), shRNA, qPCR primers, and chromatin immunoprecipitation (ChIP)-qPCR primers used in the studies of this manuscript.</title></caption><media xlink:href="elife-80854-supp1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-80854-mdarchecklist1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Source files of all original gels and Western Blots were provided for the following figures: Figure 1—figure supplement 2B; Figure 4—figure supplement 1A, C, D, E; Figure 5—figure supplement 2B, F, G. RNA sequencing and ChIP sequencing data files that support the findings of this study have been deposited in the Gene Expression Omnibus under the accession code GSE85055, as well as in the Dryad digital repository (doi:10.5061/dryad.7pvmcvdwm; doi:10.5061/dryad.f1vhhmh0h). Sequences of sgRNAs, shRNAs, and primers used in this manuscript are included in the Supplementary File 1.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Soto-Feliciano</surname><given-names>MY</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Morris</surname><given-names>JP</given-names></name><name><surname>Huang</surname><given-names>C-H</given-names></name><name><surname>Koche</surname><given-names>RP</given-names></name><name><surname>Y-J</surname><given-names>Ho</given-names></name><name><surname>Banito</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>C-W</given-names></name><name><surname>Shroff</surname><given-names>A</given-names></name><name><surname>Tian</surname><given-names>S</given-names></name><name><surname>Livshits</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>C-C</given-names></name><name><surname>Fennell</surname><given-names>M</given-names></name><name><surname>Armstrong</surname><given-names>SA</given-names></name><name><surname>Allis</surname><given-names>CD</given-names></name><name><surname>Tschaharganeh</surname><given-names>DF</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Mll3 suppresses tumorigenesis by activating the Ink4a/Arf locus</data-title><source>Dryad Digital Repository</source><pub-id pub-id-type="doi">10.5061/dryad.7pvmcvdwm</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Soto-Feliciano</surname><given-names>MY</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Morris</surname><given-names>JP</given-names></name><name><surname>Huang</surname><given-names>C-H</given-names></name><name><surname>Roche</surname><given-names>RP</given-names></name><name><surname>Y-J</surname><given-names>Ho</given-names></name><name><surname>Banito</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>C-W</given-names></name><name><surname>Shroff</surname><given-names>A</given-names></name><name><surname>Tian</surname><given-names>S</given-names></name><name><surname>Livshits</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>C-C</given-names></name><name><surname>Fennell</surname><given-names>M</given-names></name><name><surname>Armstrong</surname><given-names>SA</given-names></name><name><surname>Allis</surname><given-names>CD</given-names></name><name><surname>Tschaharganeh</surname><given-names>DF</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>MLL3 ChIP sequencing in murine and human HCC cells</data-title><source>Dryad Digital Repository</source><pub-id pub-id-type="doi">10.5061/dryad.f1vhhmh0h</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset3"><person-group person-group-type="author"><name><surname>Lowe</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2017">2017</year><data-title>Mll3 suppresses tumorigenesis by activating the Ink4a/Arf locus</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85055">GSE85055</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Charles Sherr and Janet Novak for constructive guidance and advice on all aspects of this study. We thank Ali Shilatifard, Lu Wang, and all members of the Lowe lab for helpful and stimulating discussions. We gratefully thank A Chramiec for excellent technical assistance. We thank Joanna Wysocka (Stanford University) for kindly sharing the anti-MLL3/4 antibody used in our ChIP-Seq experiments. This work was supported by grants to SWL (P01 CA013106 and R01 CA233944) from the NIH/NCI, as well as by the National Center for Tumor Disease, Heidelberg, and grants of the German Research Foundation to DFG (SFB/TRR77). This work was also supported by the NIH/NCI Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center (P30 CA008748). YMSF is supported by a MOSAIC K99/R00 Award from the NIH/NIGMS (1K99GM140265-01). CZ is supported by an F32 Postdoctoral Fellowship (1F32CA257103) from the NIH/NCI. JPM was a recipient of a Postdoctoral Fellowship (PF-14-066-01-TBE) from the American Cancer Society. DFT is supported by a Young Investigator Group (VH-NG-1114) by the Helmholtz foundation. SWL is the Geoffrey Beene Chair for Cancer Biology and an investigator of the Howard Hughes Medical Institute.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>SM</given-names></name><name><surname>Jang</surname><given-names>SJ</given-names></name><name><surname>Shim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Hong</surname><given-names>SM</given-names></name><name><surname>Sung</surname><given-names>CO</given-names></name><name><surname>Baek</surname><given-names>D</given-names></name><name><surname>Haq</surname><given-names>F</given-names></name><name><surname>Ansari</surname><given-names>AA</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Chun</surname><given-names>SM</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Choi</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Hwang</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Jung</surname><given-names>WR</given-names></name><name><surname>Jang</surname><given-names>HY</given-names></name><name><surname>Yang</surname><given-names>E</given-names></name><name><surname>Sung</surname><given-names>WK</given-names></name><name><surname>Lee</surname><given-names>NP</given-names></name><name><surname>Mao</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Zucman-Rossi</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>HC</given-names></name><name><surname>Kong</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genomic portrait of Resectable hepatocellular Carcinomas: implications of Rb1 and Fgf19 aberrations for patient stratification</article-title><source>Hepatology</source><volume>60</volume><fpage>1972</fpage><lpage>1982</lpage><pub-id pub-id-type="doi">10.1002/hep.27198</pub-id><pub-id pub-id-type="pmid">24798001</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ananthanarayanan</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Surapureddi</surname><given-names>S</given-names></name><name><surname>Balasubramaniyan</surname><given-names>N</given-names></name><name><surname>Ahn</surname><given-names>J</given-names></name><name><surname>Goldstein</surname><given-names>JA</given-names></name><name><surname>Suchy</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Histone H3K4 Trimethylation by Mll3 as part of ASCOM complex is critical for NR activation of bile acid transporter genes and is downregulated in cholestasis</article-title><source>American Journal of Physiology. Gastrointestinal and Liver Physiology</source><volume>300</volume><fpage>G771</fpage><lpage>G781</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00499.2010</pub-id><pub-id pub-id-type="pmid">21330447</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anders</surname><given-names>S</given-names></name><name><surname>Pyl</surname><given-names>PT</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Htseq--a python framework to work with high-throughput sequencing data</article-title><source>Bioinformatics</source><volume>31</volume><fpage>166</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu638</pub-id><pub-id pub-id-type="pmid">25260700</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barradas</surname><given-names>M</given-names></name><name><surname>Anderton</surname><given-names>E</given-names></name><name><surname>Acosta</surname><given-names>JC</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Banito</surname><given-names>A</given-names></name><name><surname>Rodriguez-Niedenführ</surname><given-names>M</given-names></name><name><surname>Maertens</surname><given-names>G</given-names></name><name><surname>Banck</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>MM</given-names></name><name><surname>Walsh</surname><given-names>MJ</given-names></name><name><surname>Peters</surname><given-names>G</given-names></name><name><surname>Gil</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Histone demethylase Jmjd3 contributes to epigenetic control of Ink4A/ARF by Oncogenic RAS</article-title><source>Genes &amp; Development</source><volume>23</volume><fpage>1177</fpage><lpage>1182</lpage><pub-id pub-id-type="doi">10.1101/gad.511109</pub-id><pub-id pub-id-type="pmid">19451218</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barriga</surname><given-names>FM</given-names></name><name><surname>Tsanov</surname><given-names>KM</given-names></name><name><surname>Ho</surname><given-names>YJ</given-names></name><name><surname>Sohail</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Baslan</surname><given-names>T</given-names></name><name><surname>Wuest</surname><given-names>AN</given-names></name><name><surname>Del Priore</surname><given-names>I</given-names></name><name><surname>Meškauskaitė</surname><given-names>B</given-names></name><name><surname>Livshits</surname><given-names>G</given-names></name><name><surname>Alonso-Curbelo</surname><given-names>D</given-names></name><name><surname>Simon</surname><given-names>J</given-names></name><name><surname>Chaves-Perez</surname><given-names>A</given-names></name><name><surname>Bar-Sagi</surname><given-names>D</given-names></name><name><surname>Iacobuzio-Donahue</surname><given-names>CA</given-names></name><name><surname>Notta</surname><given-names>F</given-names></name><name><surname>Chaligne</surname><given-names>R</given-names></name><name><surname>Sharma</surname><given-names>R</given-names></name><name><surname>Pe’er</surname><given-names>D</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>MACHETE identifies interferon-encompassing Chromosome 9P21.3 deletions as mediators of immune evasion and metastasis</article-title><source>Nature Cancer</source><volume>3</volume><fpage>1367</fpage><lpage>1385</lpage><pub-id pub-id-type="doi">10.1038/s43018-022-00443-5</pub-id><pub-id pub-id-type="pmid">36344707</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>JB</given-names></name><name><surname>Podetz-Pedersen</surname><given-names>KM</given-names></name><name><surname>Aronovich</surname><given-names>EL</given-names></name><name><surname>Belur</surname><given-names>LR</given-names></name><name><surname>McIvor</surname><given-names>RS</given-names></name><name><surname>Hackett</surname><given-names>PB</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Preferential delivery of the sleeping beauty Transposon system to livers of mice by Hydrodynamic injection</article-title><source>Nature Protocols</source><volume>2</volume><fpage>3153</fpage><lpage>3165</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.471</pub-id><pub-id pub-id-type="pmid">18079715</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bieging-Rolett</surname><given-names>KT</given-names></name><name><surname>Kaiser</surname><given-names>AM</given-names></name><name><surname>Morgens</surname><given-names>DW</given-names></name><name><surname>Boutelle</surname><given-names>AM</given-names></name><name><surname>Seoane</surname><given-names>JA</given-names></name><name><surname>Van Nostrand</surname><given-names>EL</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Houlihan</surname><given-names>SL</given-names></name><name><surname>Mello</surname><given-names>SS</given-names></name><name><surname>Yee</surname><given-names>BA</given-names></name><name><surname>McClendon</surname><given-names>J</given-names></name><name><surname>Pierce</surname><given-names>SE</given-names></name><name><surname>Winters</surname><given-names>IP</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Connolly</surname><given-names>AJ</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name><name><surname>Curtis</surname><given-names>C</given-names></name><name><surname>Yeo</surname><given-names>GW</given-names></name><name><surname>Winslow</surname><given-names>MM</given-names></name><name><surname>Bassik</surname><given-names>MC</given-names></name><name><surname>Attardi</surname><given-names>LD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Zmat3 is a key splicing regulator in the P53 tumor suppression program</article-title><source>Molecular Cell</source><volume>80</volume><fpage>452</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.10.022</pub-id><pub-id pub-id-type="pmid">33157015</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bracken</surname><given-names>AP</given-names></name><name><surname>Kleine-Kohlbrecher</surname><given-names>D</given-names></name><name><surname>Dietrich</surname><given-names>N</given-names></name><name><surname>Pasini</surname><given-names>D</given-names></name><name><surname>Gargiulo</surname><given-names>G</given-names></name><name><surname>Beekman</surname><given-names>C</given-names></name><name><surname>Theilgaard-Mönch</surname><given-names>K</given-names></name><name><surname>Minucci</surname><given-names>S</given-names></name><name><surname>Porse</surname><given-names>BT</given-names></name><name><surname>Marine</surname><given-names>JC</given-names></name><name><surname>Hansen</surname><given-names>KH</given-names></name><name><surname>Helin</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The Polycomb group proteins bind throughout the Ink4A-ARF locus and are disassociated in Senescent cells</article-title><source>Genes &amp; Development</source><volume>21</volume><fpage>525</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1101/gad.415507</pub-id><pub-id pub-id-type="pmid">17344414</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research Network</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Comprehensive and integrative Genomic characterization of hepatocellular carcinoma</article-title><source>Cell</source><volume>169</volume><fpage>1327</fpage><lpage>1341</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.05.046</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>Gross</surname><given-names>BE</given-names></name><name><surname>Sumer</surname><given-names>SO</given-names></name><name><surname>Aksoy</surname><given-names>BA</given-names></name><name><surname>Jacobsen</surname><given-names>A</given-names></name><name><surname>Byrne</surname><given-names>CJ</given-names></name><name><surname>Heuer</surname><given-names>ML</given-names></name><name><surname>Larsson</surname><given-names>E</given-names></name><name><surname>Antipin</surname><given-names>Y</given-names></name><name><surname>Reva</surname><given-names>B</given-names></name><name><surname>Goldberg</surname><given-names>AP</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The cBio cancer Genomics portal: an open platform for exploring multidimensional cancer Genomics data</article-title><source>Cancer Discovery</source><volume>2</volume><fpage>401</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0095</pub-id><pub-id pub-id-type="pmid">22588877</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavez</surname><given-names>A</given-names></name><name><surname>Scheiman</surname><given-names>J</given-names></name><name><surname>Vora</surname><given-names>S</given-names></name><name><surname>Pruitt</surname><given-names>BW</given-names></name><name><surname>Tuttle</surname><given-names>M</given-names></name><name><surname>P R Iyer</surname><given-names>E</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Kiani</surname><given-names>S</given-names></name><name><surname>Guzman</surname><given-names>CD</given-names></name><name><surname>Wiegand</surname><given-names>DJ</given-names></name><name><surname>Ter-Ovanesyan</surname><given-names>D</given-names></name><name><surname>Braff</surname><given-names>JL</given-names></name><name><surname>Davidsohn</surname><given-names>N</given-names></name><name><surname>Housden</surname><given-names>BE</given-names></name><name><surname>Perrimon</surname><given-names>N</given-names></name><name><surname>Weiss</surname><given-names>R</given-names></name><name><surname>Aach</surname><given-names>J</given-names></name><name><surname>Collins</surname><given-names>JJ</given-names></name><name><surname>Church</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Highly efficient Cas9-mediated transcriptional programming</article-title><source>Nature Methods</source><volume>12</volume><fpage>326</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3312</pub-id><pub-id pub-id-type="pmid">25730490</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Rappaport</surname><given-names>AR</given-names></name><name><surname>Kitzing</surname><given-names>T</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Shroff</surname><given-names>AS</given-names></name><name><surname>Dickins</surname><given-names>RA</given-names></name><name><surname>Vakoc</surname><given-names>CR</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Stock</surname><given-names>W</given-names></name><name><surname>LeBeau</surname><given-names>MM</given-names></name><name><surname>Shannon</surname><given-names>KM</given-names></name><name><surname>Kogan</surname><given-names>S</given-names></name><name><surname>Zuber</surname><given-names>J</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mll3 is a Haploinsufficient 7Q tumor Suppressor in acute myeloid leukemia</article-title><source>Cancer Cell</source><volume>25</volume><fpage>652</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2014.03.016</pub-id><pub-id pub-id-type="pmid">24794707</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Blum</surname><given-names>R</given-names></name><name><surname>Bowman</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name><name><surname>Shilatifard</surname><given-names>A</given-names></name><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Dynlacht</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A role for H3K4 Monomethylation in Gene repression and partitioning of Chromatin readers</article-title><source>Molecular Cell</source><volume>53</volume><fpage>979</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.02.032</pub-id><pub-id pub-id-type="pmid">24656132</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cleary</surname><given-names>SP</given-names></name><name><surname>Jeck</surname><given-names>WR</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Selitsky</surname><given-names>SR</given-names></name><name><surname>Savich</surname><given-names>GL</given-names></name><name><surname>Tan</surname><given-names>TX</given-names></name><name><surname>Wu</surname><given-names>MC</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Parker</surname><given-names>JS</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Powers</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Fischer</surname><given-names>S</given-names></name><name><surname>Guindi</surname><given-names>M</given-names></name><name><surname>Ghanekar</surname><given-names>A</given-names></name><name><surname>Chiang</surname><given-names>DY</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Identification of driver genes in hepatocellular carcinoma by Exome sequencing</article-title><source>Hepatology</source><volume>58</volume><fpage>1693</fpage><lpage>1702</lpage><pub-id pub-id-type="doi">10.1002/hep.26540</pub-id><pub-id pub-id-type="pmid">23728943</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denissov</surname><given-names>S</given-names></name><name><surname>Hofemeister</surname><given-names>H</given-names></name><name><surname>Marks</surname><given-names>H</given-names></name><name><surname>Kranz</surname><given-names>A</given-names></name><name><surname>Ciotta</surname><given-names>G</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Anastassiadis</surname><given-names>K</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>Stewart</surname><given-names>AF</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mll2 is required for H3K4 Trimethylation on Bivalent promoters in embryonic stem cells, whereas Mll1 is redundant</article-title><source>Development</source><volume>141</volume><fpage>526</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1242/dev.102681</pub-id><pub-id pub-id-type="pmid">24423662</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhar</surname><given-names>SS</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Oh</surname><given-names>W</given-names></name><name><surname>Allton</surname><given-names>K</given-names></name><name><surname>Gafni</surname><given-names>O</given-names></name><name><surname>Kim</surname><given-names>YZ</given-names></name><name><surname>Tomoiga</surname><given-names>AS</given-names></name><name><surname>Barton</surname><given-names>MC</given-names></name><name><surname>Hanna</surname><given-names>JH</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>An essential role for UTX in resolution and activation of Bivalent promoters</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>3659</fpage><lpage>3674</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv1516</pub-id><pub-id pub-id-type="pmid">26762983</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickins</surname><given-names>RA</given-names></name><name><surname>Hemann</surname><given-names>MT</given-names></name><name><surname>Zilfou</surname><given-names>JT</given-names></name><name><surname>Simpson</surname><given-names>DR</given-names></name><name><surname>Ibarra</surname><given-names>I</given-names></name><name><surname>Hannon</surname><given-names>GJ</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Probing tumor phenotypes using stable and regulated synthetic microRNA precursors</article-title><source>Nature Genetics</source><volume>37</volume><fpage>1289</fpage><lpage>1295</lpage><pub-id pub-id-type="doi">10.1038/ng1651</pub-id><pub-id pub-id-type="pmid">16200064</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Batut</surname><given-names>P</given-names></name><name><surname>Chaisson</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: Ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorighi</surname><given-names>KM</given-names></name><name><surname>Swigut</surname><given-names>T</given-names></name><name><surname>Henriques</surname><given-names>T</given-names></name><name><surname>Bhanu</surname><given-names>NV</given-names></name><name><surname>Scruggs</surname><given-names>BS</given-names></name><name><surname>Nady</surname><given-names>N</given-names></name><name><surname>Still</surname><given-names>CD</given-names></name><name><surname>Garcia</surname><given-names>BA</given-names></name><name><surname>Adelman</surname><given-names>K</given-names></name><name><surname>Wysocka</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mll3 and Mll4 facilitate enhancer RNA synthesis and transcription from promoters independently of H3K4 Monomethylation</article-title><source>Molecular Cell</source><volume>66</volume><fpage>568</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2017.04.018</pub-id><pub-id pub-id-type="pmid">28483418</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egolf</surname><given-names>S</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>A</given-names></name><name><surname>Simpson</surname><given-names>CL</given-names></name><name><surname>Aubert</surname><given-names>Y</given-names></name><name><surname>Prouty</surname><given-names>S</given-names></name><name><surname>Ge</surname><given-names>K</given-names></name><name><surname>Seykora</surname><given-names>JT</given-names></name><name><surname>Capell</surname><given-names>BC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mll4 mediates differentiation and tumor suppression through Ferroptosis</article-title><source>Science Advances</source><volume>7</volume><elocation-id>eabj9141</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abj9141</pub-id><pub-id pub-id-type="pmid">34890228</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eischen</surname><given-names>CM</given-names></name><name><surname>Weber</surname><given-names>JD</given-names></name><name><surname>Roussel</surname><given-names>MF</given-names></name><name><surname>Sherr</surname><given-names>CJ</given-names></name><name><surname>Cleveland</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Disruption of the ARF-Mdm2-P53 tumor Suppressor pathway in Myc-induced Lymphomagenesis</article-title><source>Genes &amp; Development</source><volume>13</volume><fpage>2658</fpage><lpage>2669</lpage><pub-id pub-id-type="doi">10.1101/gad.13.20.2658</pub-id><pub-id pub-id-type="pmid">10541552</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evan</surname><given-names>GI</given-names></name><name><surname>Wyllie</surname><given-names>AH</given-names></name><name><surname>Gilbert</surname><given-names>CS</given-names></name><name><surname>Littlewood</surname><given-names>TD</given-names></name><name><surname>Land</surname><given-names>H</given-names></name><name><surname>Brooks</surname><given-names>M</given-names></name><name><surname>Waters</surname><given-names>CM</given-names></name><name><surname>Penn</surname><given-names>LZ</given-names></name><name><surname>Hancock</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Induction of apoptosis in fibroblasts by C-Myc protein</article-title><source>Cell</source><volume>69</volume><fpage>119</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(92)90123-t</pub-id><pub-id pub-id-type="pmid">1555236</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fountain</surname><given-names>JW</given-names></name><name><surname>Karayiorgou</surname><given-names>M</given-names></name><name><surname>Taruscio</surname><given-names>D</given-names></name><name><surname>Graw</surname><given-names>SL</given-names></name><name><surname>Buckler</surname><given-names>AJ</given-names></name><name><surname>Ward</surname><given-names>DC</given-names></name><name><surname>Dracopoli</surname><given-names>NC</given-names></name><name><surname>Housman</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Genetic and physical map of the interferon region on Chromosome 9p</article-title><source>Genomics</source><volume>14</volume><fpage>105</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/s0888-7543(05)80290-3</pub-id><pub-id pub-id-type="pmid">1385297</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimoto</surname><given-names>A</given-names></name><name><surname>Totoki</surname><given-names>Y</given-names></name><name><surname>Abe</surname><given-names>T</given-names></name><name><surname>Boroevich</surname><given-names>KA</given-names></name><name><surname>Hosoda</surname><given-names>F</given-names></name><name><surname>Nguyen</surname><given-names>HH</given-names></name><name><surname>Aoki</surname><given-names>M</given-names></name><name><surname>Hosono</surname><given-names>N</given-names></name><name><surname>Kubo</surname><given-names>M</given-names></name><name><surname>Miya</surname><given-names>F</given-names></name><name><surname>Arai</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Shirakihara</surname><given-names>T</given-names></name><name><surname>Nagasaki</surname><given-names>M</given-names></name><name><surname>Shibuya</surname><given-names>T</given-names></name><name><surname>Nakano</surname><given-names>K</given-names></name><name><surname>Watanabe-Makino</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Kusuda</surname><given-names>J</given-names></name><name><surname>Ojima</surname><given-names>H</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Okusaka</surname><given-names>T</given-names></name><name><surname>Ueno</surname><given-names>M</given-names></name><name><surname>Shigekawa</surname><given-names>Y</given-names></name><name><surname>Kawakami</surname><given-names>Y</given-names></name><name><surname>Arihiro</surname><given-names>K</given-names></name><name><surname>Ohdan</surname><given-names>H</given-names></name><name><surname>Gotoh</surname><given-names>K</given-names></name><name><surname>Ishikawa</surname><given-names>O</given-names></name><name><surname>Ariizumi</surname><given-names>SI</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Chayama</surname><given-names>K</given-names></name><name><surname>Kosuge</surname><given-names>T</given-names></name><name><surname>Yamaue</surname><given-names>H</given-names></name><name><surname>Kamatani</surname><given-names>N</given-names></name><name><surname>Miyano</surname><given-names>S</given-names></name><name><surname>Nakagama</surname><given-names>H</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Tsunoda</surname><given-names>T</given-names></name><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>Nakagawa</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Whole-genome sequencing of liver cancers identifies Etiological influences on Mutation patterns and recurrent mutations in Chromatin regulators</article-title><source>Nature Genetics</source><volume>44</volume><fpage>760</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1038/ng.2291</pub-id><pub-id pub-id-type="pmid">22634756</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Aksoy</surname><given-names>BA</given-names></name><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>Dresdner</surname><given-names>G</given-names></name><name><surname>Gross</surname><given-names>B</given-names></name><name><surname>Sumer</surname><given-names>SO</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Jacobsen</surname><given-names>A</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Larsson</surname><given-names>E</given-names></name><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Integrative analysis of complex cancer Genomics and clinical profiles using the cBioPortal</article-title><source>Science Signaling</source><volume>6</volume><elocation-id>pl1</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2004088</pub-id><pub-id pub-id-type="pmid">23550210</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gil</surname><given-names>J</given-names></name><name><surname>Peters</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Regulation of the Ink4B-ARF-Ink4A tumour Suppressor locus: all for one or one for all</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>7</volume><fpage>667</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1038/nrm1987</pub-id><pub-id pub-id-type="pmid">16921403</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname><given-names>JJ</given-names></name><name><surname>Nandakumar</surname><given-names>S</given-names></name><name><surname>Armenia</surname><given-names>J</given-names></name><name><surname>Khalil</surname><given-names>DN</given-names></name><name><surname>Albano</surname><given-names>M</given-names></name><name><surname>Ly</surname><given-names>M</given-names></name><name><surname>Shia</surname><given-names>J</given-names></name><name><surname>Hechtman</surname><given-names>JF</given-names></name><name><surname>Kundra</surname><given-names>R</given-names></name><name><surname>El Dika</surname><given-names>I</given-names></name><name><surname>Do</surname><given-names>RK</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Kingham</surname><given-names>TP</given-names></name><name><surname>D’Angelica</surname><given-names>MI</given-names></name><name><surname>Berger</surname><given-names>MF</given-names></name><name><surname>Hyman</surname><given-names>DM</given-names></name><name><surname>Jarnagin</surname><given-names>W</given-names></name><name><surname>Klimstra</surname><given-names>DS</given-names></name><name><surname>Janjigian</surname><given-names>YY</given-names></name><name><surname>Solit</surname><given-names>DB</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Abou-Alfa</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Prospective Genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies</article-title><source>Clinical Cancer Research</source><volume>25</volume><fpage>2116</fpage><lpage>2126</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-2293</pub-id><pub-id pub-id-type="pmid">30373752</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herz</surname><given-names>HM</given-names></name><name><surname>Madden</surname><given-names>LD</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Bolduc</surname><given-names>C</given-names></name><name><surname>Buff</surname><given-names>E</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Davuluri</surname><given-names>R</given-names></name><name><surname>Shilatifard</surname><given-names>A</given-names></name><name><surname>Hariharan</surname><given-names>IK</given-names></name><name><surname>Bergmann</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The H3K27Me3 demethylase dUTX is a Suppressor of Notch- and RB-dependent tumors in <italic>Drosophila</italic></article-title><source>Molecular and Cellular Biology</source><volume>30</volume><fpage>2485</fpage><lpage>2497</lpage><pub-id pub-id-type="doi">10.1128/MCB.01633-09</pub-id><pub-id pub-id-type="pmid">20212086</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herz</surname><given-names>HM</given-names></name><name><surname>Mohan</surname><given-names>M</given-names></name><name><surname>Garruss</surname><given-names>AS</given-names></name><name><surname>Liang</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>YH</given-names></name><name><surname>Mickey</surname><given-names>K</given-names></name><name><surname>Voets</surname><given-names>O</given-names></name><name><surname>Verrijzer</surname><given-names>CP</given-names></name><name><surname>Shilatifard</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Enhancer-associated H3K4 monomethylation by Trithorax-related, the <italic>Drosophila</italic> homolog of mammalian Mll3/Mll4</article-title><source>Genes &amp; Development</source><volume>26</volume><fpage>2604</fpage><lpage>2620</lpage><pub-id pub-id-type="doi">10.1101/gad.201327.112</pub-id><pub-id pub-id-type="pmid">23166019</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>PD</given-names></name><name><surname>Scott</surname><given-names>DA</given-names></name><name><surname>Weinstein</surname><given-names>JA</given-names></name><name><surname>Ran</surname><given-names>FA</given-names></name><name><surname>Konermann</surname><given-names>S</given-names></name><name><surname>Agarwala</surname><given-names>V</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Fine</surname><given-names>EJ</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Shalem</surname><given-names>O</given-names></name><name><surname>Cradick</surname><given-names>TJ</given-names></name><name><surname>Marraffini</surname><given-names>LA</given-names></name><name><surname>Bao</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>DNA targeting specificity of RNA-guided Cas9 nucleases</article-title><source>Nature Biotechnology</source><volume>31</volume><fpage>827</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1038/nbt.2647</pub-id><pub-id pub-id-type="pmid">23873081</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>D</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Morgan</surname><given-names>MA</given-names></name><name><surname>Herz</surname><given-names>HM</given-names></name><name><surname>Smith</surname><given-names>ER</given-names></name><name><surname>Shilatifard</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The Mll3/Mll4 branches of the COMPASS family function as major Histone H3K4 Monomethylases at enhancers</article-title><source>Molecular and Cellular Biology</source><volume>33</volume><fpage>4745</fpage><lpage>4754</lpage><pub-id pub-id-type="doi">10.1128/MCB.01181-13</pub-id><pub-id pub-id-type="pmid">24081332</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>CH</given-names></name><name><surname>Lujambio</surname><given-names>A</given-names></name><name><surname>Zuber</surname><given-names>J</given-names></name><name><surname>Tschaharganeh</surname><given-names>DF</given-names></name><name><surname>Doran</surname><given-names>MG</given-names></name><name><surname>Evans</surname><given-names>MJ</given-names></name><name><surname>Kitzing</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>N</given-names></name><name><surname>de Stanchina</surname><given-names>E</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name><name><surname>Armstrong</surname><given-names>SA</given-names></name><name><surname>Lewis</surname><given-names>JS</given-names></name><name><surname>Sherr</surname><given-names>CJ</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cdk9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma</article-title><source>Genes &amp; Development</source><volume>28</volume><fpage>1800</fpage><lpage>1814</lpage><pub-id pub-id-type="doi">10.1101/gad.244368.114</pub-id><pub-id pub-id-type="pmid">25128497</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>JJ</given-names></name><name><surname>Scheijen</surname><given-names>B</given-names></name><name><surname>Voncken</surname><given-names>JW</given-names></name><name><surname>Kieboom</surname><given-names>K</given-names></name><name><surname>Berns</surname><given-names>A</given-names></name><name><surname>van Lohuizen</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Bmi-1 Collaborates with C-Myc in tumorigenesis by inhibiting C-Myc-induced apoptosis via Ink4A/ARF</article-title><source>Genes &amp; Development</source><volume>13</volume><fpage>2678</fpage><lpage>2690</lpage><pub-id pub-id-type="doi">10.1101/gad.13.20.2678</pub-id><pub-id pub-id-type="pmid">10541554</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Ward</surname><given-names>EM</given-names></name><name><surname>Johnson</surname><given-names>CJ</given-names></name><name><surname>Cronin</surname><given-names>KA</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Ryerson</surname><given-names>AB</given-names></name><name><surname>Mariotto</surname><given-names>A</given-names></name><name><surname>Lake</surname><given-names>AJ</given-names></name><name><surname>Wilson</surname><given-names>R</given-names></name><name><surname>Sherman</surname><given-names>RL</given-names></name><name><surname>Anderson</surname><given-names>RN</given-names></name><name><surname>Henley</surname><given-names>SJ</given-names></name><name><surname>Kohler</surname><given-names>BA</given-names></name><name><surname>Penberthy</surname><given-names>L</given-names></name><name><surname>Feuer</surname><given-names>EJ</given-names></name><name><surname>Weir</surname><given-names>HK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Annual report to the nation on the status of cancer, 1975-2014</article-title><source>Journal of the National Cancer Institute</source><volume>109</volume><elocation-id>djx030</elocation-id><pub-id pub-id-type="doi">10.1093/jnci/djx030</pub-id><pub-id pub-id-type="pmid">28376154</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kan</surname><given-names>Z</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Barber</surname><given-names>TD</given-names></name><name><surname>Gong</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Hao</surname><given-names>K</given-names></name><name><surname>Willard</surname><given-names>MD</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Hauptschein</surname><given-names>R</given-names></name><name><surname>Rejto</surname><given-names>PA</given-names></name><name><surname>Fernandez</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>NP</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Peng</surname><given-names>Z</given-names></name><name><surname>Yi</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>R</given-names></name><name><surname>Ju</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Estrella</surname><given-names>H</given-names></name><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>P</given-names></name><name><surname>Qiu</surname><given-names>M</given-names></name><name><surname>Wulur</surname><given-names>IH</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Ehsani</surname><given-names>ME</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Loboda</surname><given-names>A</given-names></name><name><surname>Sung</surname><given-names>WK</given-names></name><name><surname>Aggarwal</surname><given-names>A</given-names></name><name><surname>Poon</surname><given-names>RT</given-names></name><name><surname>Fan</surname><given-names>ST</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Hardwick</surname><given-names>J</given-names></name><name><surname>Reinhard</surname><given-names>C</given-names></name><name><surname>Dai</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Luk</surname><given-names>JM</given-names></name><name><surname>Mao</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma</article-title><source>Genome Research</source><volume>23</volume><fpage>1422</fpage><lpage>1433</lpage><pub-id pub-id-type="doi">10.1101/gr.154492.113</pub-id><pub-id pub-id-type="pmid">23788652</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knudsen</surname><given-names>ES</given-names></name><name><surname>Nambiar</surname><given-names>R</given-names></name><name><surname>Rosario</surname><given-names>SR</given-names></name><name><surname>Smiraglia</surname><given-names>DJ</given-names></name><name><surname>Goodrich</surname><given-names>DW</given-names></name><name><surname>Witkiewicz</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pan-cancer molecular analysis of the RB tumor Suppressor pathway</article-title><source>Communications Biology</source><volume>3</volume><elocation-id>158</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-020-0873-9</pub-id><pub-id pub-id-type="pmid">32242058</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotake</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Viatour</surname><given-names>P</given-names></name><name><surname>Sage</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>pRB family proteins are required for H3K27 Trimethylation and Polycomb repression complexes binding to and silencing P16Ink4Alpha tumor Suppressor Gene</article-title><source>Genes &amp; Development</source><volume>21</volume><fpage>49</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1101/gad.1499407</pub-id><pub-id pub-id-type="pmid">17210787</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Largaespada</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Transposon-mediated Mutagenesis of somatic cells in the mouse for cancer Gene identification</article-title><source>Methods</source><volume>49</volume><fpage>282</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2009.07.002</pub-id><pub-id pub-id-type="pmid">19607923</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>TI</given-names></name><name><surname>Johnstone</surname><given-names>SE</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Chromatin Immunoprecipitation and Microarray-based analysis of protein location</article-title><source>Nature Protocols</source><volume>1</volume><fpage>729</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.98</pub-id><pub-id pub-id-type="pmid">17406303</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>QH</given-names></name><name><surname>Lee</surname><given-names>DK</given-names></name><name><surname>Lee</surname><given-names>SK</given-names></name><name><surname>Roeder</surname><given-names>RG</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A tumor suppressive coactivator complex of P53 containing ASC-2 and Histone H3-Lysine-4 Methyltransferase Mll3 or its Paralogue Mll4</article-title><source>PNAS</source><volume>106</volume><fpage>8513</fpage><lpage>8518</lpage><pub-id pub-id-type="doi">10.1073/pnas.0902873106</pub-id><pub-id pub-id-type="pmid">19433796</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Kelley</surname><given-names>RK</given-names></name><name><surname>Villanueva</surname><given-names>A</given-names></name><name><surname>Singal</surname><given-names>AG</given-names></name><name><surname>Pikarsky</surname><given-names>E</given-names></name><name><surname>Roayaie</surname><given-names>S</given-names></name><name><surname>Lencioni</surname><given-names>R</given-names></name><name><surname>Koike</surname><given-names>K</given-names></name><name><surname>Zucman-Rossi</surname><given-names>J</given-names></name><name><surname>Finn</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Hepatocellular carcinoma</article-title><source>Nature Reviews. Disease Primers</source><volume>7</volume><elocation-id>6</elocation-id><pub-id pub-id-type="doi">10.1038/s41572-020-00240-3</pub-id><pub-id pub-id-type="pmid">33479224</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowe</surname><given-names>SW</given-names></name><name><surname>Sherr</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Tumor suppression by Ink4A-ARF: progress and puzzles</article-title><source>Current Opinion in Genetics &amp; Development</source><volume>13</volume><fpage>77</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/s0959-437x(02)00013-8</pub-id><pub-id pub-id-type="pmid">12573439</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Throwing the cancer switch: reciprocal roles of Polycomb and Trithorax proteins</article-title><source>Nature Reviews. Cancer</source><volume>10</volume><fpage>669</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nrc2931</pub-id><pub-id pub-id-type="pmid">20865010</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molina-Sánchez</surname><given-names>P</given-names></name><name><surname>Ruiz de Galarreta</surname><given-names>M</given-names></name><name><surname>Yao</surname><given-names>MA</given-names></name><name><surname>Lindblad</surname><given-names>KE</given-names></name><name><surname>Bresnahan</surname><given-names>E</given-names></name><name><surname>Bitterman</surname><given-names>E</given-names></name><name><surname>Martin</surname><given-names>TC</given-names></name><name><surname>Rubenstein</surname><given-names>T</given-names></name><name><surname>Nie</surname><given-names>K</given-names></name><name><surname>Golas</surname><given-names>J</given-names></name><name><surname>Choudhary</surname><given-names>S</given-names></name><name><surname>Bárcena-Varela</surname><given-names>M</given-names></name><name><surname>Elmas</surname><given-names>A</given-names></name><name><surname>Miguela</surname><given-names>V</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Kan</surname><given-names>Z</given-names></name><name><surname>Grinspan</surname><given-names>LT</given-names></name><name><surname>Huang</surname><given-names>KL</given-names></name><name><surname>Parsons</surname><given-names>RE</given-names></name><name><surname>Shields</surname><given-names>DJ</given-names></name><name><surname>Rollins</surname><given-names>RA</given-names></name><name><surname>Lujambio</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cooperation between distinct cancer driver genes underlies Intertumor heterogeneity in hepatocellular carcinoma</article-title><source>Gastroenterology</source><volume>159</volume><fpage>2203</fpage><lpage>2220</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2020.08.015</pub-id><pub-id pub-id-type="pmid">32814112</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>SH</given-names></name><name><surname>Huang</surname><given-names>CH</given-names></name><name><surname>Houlihan</surname><given-names>SL</given-names></name><name><surname>Regunath</surname><given-names>K</given-names></name><name><surname>Freed-Pastor</surname><given-names>WA</given-names></name><name><surname>Morris</surname><given-names>JP</given-names></name><name><surname>Tschaharganeh</surname><given-names>DF</given-names></name><name><surname>Kastenhuber</surname><given-names>ER</given-names></name><name><surname>Barsotti</surname><given-names>AM</given-names></name><name><surname>Culp-Hill</surname><given-names>R</given-names></name><name><surname>Xue</surname><given-names>W</given-names></name><name><surname>Ho</surname><given-names>YJ</given-names></name><name><surname>Baslan</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Mayle</surname><given-names>A</given-names></name><name><surname>de Stanchina</surname><given-names>E</given-names></name><name><surname>Zender</surname><given-names>L</given-names></name><name><surname>Tong</surname><given-names>DR</given-names></name><name><surname>D’Alessandro</surname><given-names>A</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name><name><surname>Prives</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>P53 represses the Mevalonate pathway to mediate tumor suppression</article-title><source>Cell</source><volume>176</volume><fpage>564</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.11.011</pub-id><pub-id pub-id-type="pmid">30580964</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negoescu</surname><given-names>A</given-names></name><name><surname>Lorimier</surname><given-names>P</given-names></name><name><surname>Labat-Moleur</surname><given-names>F</given-names></name><name><surname>Azoti</surname><given-names>L</given-names></name><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Guillermet</surname><given-names>C</given-names></name><name><surname>Brambilla</surname><given-names>C</given-names></name><name><surname>Brambilla</surname><given-names>E</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>TUNEL: Improvement and evaluation of the method for in situ apoptotic cell identification</article-title><source>Biochemica</source><volume>2</volume><fpage>12</fpage><lpage>17</lpage></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>CKY</given-names></name><name><surname>Dazert</surname><given-names>E</given-names></name><name><surname>Boldanova</surname><given-names>T</given-names></name><name><surname>Coto-Llerena</surname><given-names>M</given-names></name><name><surname>Nuciforo</surname><given-names>S</given-names></name><name><surname>Ercan</surname><given-names>C</given-names></name><name><surname>Suslov</surname><given-names>A</given-names></name><name><surname>Meier</surname><given-names>MA</given-names></name><name><surname>Bock</surname><given-names>T</given-names></name><name><surname>Schmidt</surname><given-names>A</given-names></name><name><surname>Ketterer</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wieland</surname><given-names>S</given-names></name><name><surname>Matter</surname><given-names>MS</given-names></name><name><surname>Colombi</surname><given-names>M</given-names></name><name><surname>Piscuoglio</surname><given-names>S</given-names></name><name><surname>Terracciano</surname><given-names>LM</given-names></name><name><surname>Hall</surname><given-names>MN</given-names></name><name><surname>Heim</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Integrative Proteogenomic characterization of hepatocellular carcinoma across Etiologies and stages</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>2436</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-29960-8</pub-id><pub-id pub-id-type="pmid">35508466</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panigrahi</surname><given-names>A</given-names></name><name><surname>O’Malley</surname><given-names>BW</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mechanisms of enhancer action: the known and the unknown</article-title><source>Genome Biology</source><volume>22</volume><elocation-id>108</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-021-02322-1</pub-id><pub-id pub-id-type="pmid">33858480</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piunti</surname><given-names>A</given-names></name><name><surname>Shilatifard</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Epigenetic balance of gene expression by Polycomb and COMPASS families</article-title><source>Science</source><volume>352</volume><elocation-id>aad9780</elocation-id><pub-id pub-id-type="doi">10.1126/science.aad9780</pub-id><pub-id pub-id-type="pmid">27257261</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rebouissou</surname><given-names>S</given-names></name><name><surname>Franconi</surname><given-names>A</given-names></name><name><surname>Calderaro</surname><given-names>J</given-names></name><name><surname>Letouzé</surname><given-names>E</given-names></name><name><surname>Imbeaud</surname><given-names>S</given-names></name><name><surname>Pilati</surname><given-names>C</given-names></name><name><surname>Nault</surname><given-names>JC</given-names></name><name><surname>Couchy</surname><given-names>G</given-names></name><name><surname>Laurent</surname><given-names>A</given-names></name><name><surname>Balabaud</surname><given-names>C</given-names></name><name><surname>Bioulac-Sage</surname><given-names>P</given-names></name><name><surname>Zucman-Rossi</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genotype-phenotype correlation of Ctnnb1 mutations reveals different SS-Catenin activity associated with liver tumor progression</article-title><source>Hepatology</source><volume>64</volume><fpage>2047</fpage><lpage>2061</lpage><pub-id pub-id-type="doi">10.1002/hep.28638</pub-id><pub-id pub-id-type="pmid">27177928</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Revia</surname><given-names>S</given-names></name><name><surname>Seretny</surname><given-names>A</given-names></name><name><surname>Wendler</surname><given-names>L</given-names></name><name><surname>Banito</surname><given-names>A</given-names></name><name><surname>Eckert</surname><given-names>C</given-names></name><name><surname>Breuer</surname><given-names>K</given-names></name><name><surname>Mayakonda</surname><given-names>A</given-names></name><name><surname>Lutsik</surname><given-names>P</given-names></name><name><surname>Evert</surname><given-names>M</given-names></name><name><surname>Ribback</surname><given-names>S</given-names></name><name><surname>Gallage</surname><given-names>S</given-names></name><name><surname>Chikh Bakri</surname><given-names>I</given-names></name><name><surname>Breuhahn</surname><given-names>K</given-names></name><name><surname>Schirmacher</surname><given-names>P</given-names></name><name><surname>Heinrich</surname><given-names>S</given-names></name><name><surname>Gaida</surname><given-names>MM</given-names></name><name><surname>Heikenwälder</surname><given-names>M</given-names></name><name><surname>Calvisi</surname><given-names>DF</given-names></name><name><surname>Plass</surname><given-names>C</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name><name><surname>Tschaharganeh</surname><given-names>DF</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Histone H3K27 demethylase Kdm6A is an epigenetic Gatekeeper of Mtorc1 signalling in cancer</article-title><source>Gut</source><volume>71</volume><fpage>1613</fpage><lpage>1628</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2021-325405</pub-id><pub-id pub-id-type="pmid">34509979</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richly</surname><given-names>H</given-names></name><name><surname>Aloia</surname><given-names>L</given-names></name><name><surname>Di Croce</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Roles of the Polycomb group proteins in stem cells and cancer</article-title><source>Cell Death &amp; Disease</source><volume>2</volume><elocation-id>e204</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2011.84</pub-id><pub-id pub-id-type="pmid">21881606</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rickels</surname><given-names>R</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name><name><surname>Collings</surname><given-names>CK</given-names></name><name><surname>Woodfin</surname><given-names>AR</given-names></name><name><surname>Piunti</surname><given-names>A</given-names></name><name><surname>Mohan</surname><given-names>M</given-names></name><name><surname>Herz</surname><given-names>HM</given-names></name><name><surname>Kvon</surname><given-names>E</given-names></name><name><surname>Shilatifard</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>An evolutionary conserved epigenetic mark of Polycomb response elements implemented by TRX/MLL/COMPASS</article-title><source>Molecular Cell</source><volume>63</volume><fpage>318</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2016.06.018</pub-id><pub-id pub-id-type="pmid">27447986</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satoh</surname><given-names>S</given-names></name><name><surname>Daigo</surname><given-names>Y</given-names></name><name><surname>Furukawa</surname><given-names>Y</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Miwa</surname><given-names>N</given-names></name><name><surname>Nishiwaki</surname><given-names>T</given-names></name><name><surname>Kawasoe</surname><given-names>T</given-names></name><name><surname>Ishiguro</surname><given-names>H</given-names></name><name><surname>Fujita</surname><given-names>M</given-names></name><name><surname>Tokino</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Imaoka</surname><given-names>S</given-names></name><name><surname>Murata</surname><given-names>M</given-names></name><name><surname>Shimano</surname><given-names>T</given-names></name><name><surname>Yamaoka</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Axin1 mutations in hepatocellular Carcinomas, and growth suppression in cancer cells by virus-mediated transfer of Axin1</article-title><source>Nature Genetics</source><volume>24</volume><fpage>245</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1038/73448</pub-id><pub-id pub-id-type="pmid">10700176</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>M</given-names></name><name><surname>Sen</surname><given-names>M</given-names></name><name><surname>Rosenbach</surname><given-names>MD</given-names></name><name><surname>Carrera</surname><given-names>CJ</given-names></name><name><surname>Friedman</surname><given-names>H</given-names></name><name><surname>Carson</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A Methylthioadenosine Phosphorylase (MTAP) fusion transcript identifies a new Gene on Chromosome 9P21 that is frequently deleted in cancer</article-title><source>Oncogene</source><volume>19</volume><fpage>5747</fpage><lpage>5754</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1203942</pub-id><pub-id pub-id-type="pmid">11126361</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>CA</given-names></name><name><surname>McCurrach</surname><given-names>ME</given-names></name><name><surname>de Stanchina</surname><given-names>E</given-names></name><name><surname>Wallace-Brodeur</surname><given-names>RR</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Ink4A/ARF mutations accelerate Lymphomagenesis and promote Chemoresistance by disabling P53</article-title><source>Genes &amp; Development</source><volume>13</volume><fpage>2670</fpage><lpage>2677</lpage><pub-id pub-id-type="doi">10.1101/gad.13.20.2670</pub-id><pub-id pub-id-type="pmid">10541553</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuettengruber</surname><given-names>B</given-names></name><name><surname>Bourbon</surname><given-names>HM</given-names></name><name><surname>Di Croce</surname><given-names>L</given-names></name><name><surname>Cavalli</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genome regulation by Polycomb and Trithorax: 70 years and counting</article-title><source>Cell</source><volume>171</volume><fpage>34</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.08.002</pub-id><pub-id pub-id-type="pmid">28938122</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulze</surname><given-names>K</given-names></name><name><surname>Imbeaud</surname><given-names>S</given-names></name><name><surname>Letouzé</surname><given-names>E</given-names></name><name><surname>Alexandrov</surname><given-names>LB</given-names></name><name><surname>Calderaro</surname><given-names>J</given-names></name><name><surname>Rebouissou</surname><given-names>S</given-names></name><name><surname>Couchy</surname><given-names>G</given-names></name><name><surname>Meiller</surname><given-names>C</given-names></name><name><surname>Shinde</surname><given-names>J</given-names></name><name><surname>Soysouvanh</surname><given-names>F</given-names></name><name><surname>Calatayud</surname><given-names>AL</given-names></name><name><surname>Pinyol</surname><given-names>R</given-names></name><name><surname>Pelletier</surname><given-names>L</given-names></name><name><surname>Balabaud</surname><given-names>C</given-names></name><name><surname>Laurent</surname><given-names>A</given-names></name><name><surname>Blanc</surname><given-names>JF</given-names></name><name><surname>Mazzaferro</surname><given-names>V</given-names></name><name><surname>Calvo</surname><given-names>F</given-names></name><name><surname>Villanueva</surname><given-names>A</given-names></name><name><surname>Nault</surname><given-names>JC</given-names></name><name><surname>Bioulac-Sage</surname><given-names>P</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Zucman-Rossi</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Exome sequencing of hepatocellular Carcinomas identifies new mutational signatures and potential therapeutic targets</article-title><source>Nature Genetics</source><volume>47</volume><fpage>505</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1038/ng.3252</pub-id><pub-id pub-id-type="pmid">25822088</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherr</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Ink4-ARF locus in cancer and aging</article-title><source>Wiley Interdisciplinary Reviews. Developmental Biology</source><volume>1</volume><fpage>731</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1002/wdev.40</pub-id><pub-id pub-id-type="pmid">22960768</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shilatifard</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The COMPASS family of Histone H3K4 Methylases: mechanisms of regulation in development and disease pathogenesis</article-title><source>Annual Review of Biochemistry</source><volume>81</volume><fpage>65</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-051710-134100</pub-id><pub-id pub-id-type="pmid">22663077</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soto-Feliciano</surname><given-names>YM</given-names></name><name><surname>Sánchez-Rivera</surname><given-names>FJ</given-names></name><name><surname>Perner</surname><given-names>F</given-names></name><name><surname>Barrows</surname><given-names>DW</given-names></name><name><surname>Kastenhuber</surname><given-names>ER</given-names></name><name><surname>Ho</surname><given-names>Y-J</given-names></name><name><surname>Carroll</surname><given-names>T</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Anand</surname><given-names>D</given-names></name><name><surname>Soshnev</surname><given-names>AA</given-names></name><name><surname>Gates</surname><given-names>L</given-names></name><name><surname>Beytagh</surname><given-names>MC</given-names></name><name><surname>Cheon</surname><given-names>D</given-names></name><name><surname>Gu</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>XS</given-names></name><name><surname>Krivtsov</surname><given-names>AV</given-names></name><name><surname>Meneses</surname><given-names>M</given-names></name><name><surname>de Stanchina</surname><given-names>E</given-names></name><name><surname>Stone</surname><given-names>RM</given-names></name><name><surname>Armstrong</surname><given-names>SA</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name><name><surname>Allis</surname><given-names>CD</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>A molecular switch between mammalian MLL complexes dictates response to Menin-MLL inhibition</article-title><source>Cancer Discovery</source><volume>13</volume><fpage>146</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-22-0416</pub-id><pub-id pub-id-type="pmid">36264143</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stott</surname><given-names>FJ</given-names></name><name><surname>Bates</surname><given-names>S</given-names></name><name><surname>James</surname><given-names>MC</given-names></name><name><surname>McConnell</surname><given-names>BB</given-names></name><name><surname>Starborg</surname><given-names>M</given-names></name><name><surname>Brookes</surname><given-names>S</given-names></name><name><surname>Palmero</surname><given-names>I</given-names></name><name><surname>Ryan</surname><given-names>K</given-names></name><name><surname>Hara</surname><given-names>E</given-names></name><name><surname>Vousden</surname><given-names>KH</given-names></name><name><surname>Peters</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The alternative product from the human Cdkn2A locus, P14(ARF), participates in a regulatory feedback loop with P53 and Mdm2</article-title><source>The EMBO Journal</source><volume>17</volume><fpage>5001</fpage><lpage>5014</lpage><pub-id pub-id-type="doi">10.1093/emboj/17.17.5001</pub-id><pub-id pub-id-type="pmid">9724636</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>SC</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Jia</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Gopal</surname><given-names>P</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Nassour</surname><given-names>I</given-names></name><name><surname>Chuang</surname><given-names>JC</given-names></name><name><surname>Maples</surname><given-names>T</given-names></name><name><surname>Celen</surname><given-names>C</given-names></name><name><surname>Nguyen</surname><given-names>LH</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Hui</surname><given-names>L</given-names></name><name><surname>Tian</surname><given-names>F</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Sorouri</surname><given-names>M</given-names></name><name><surname>Hwang</surname><given-names>TH</given-names></name><name><surname>Letzig</surname><given-names>L</given-names></name><name><surname>James</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Yopp</surname><given-names>AC</given-names></name><name><surname>Singal</surname><given-names>AG</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Arid1A has context-dependent Oncogenic and tumor Suppressor functions in liver cancer</article-title><source>Cancer Cell</source><volume>32</volume><fpage>574</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.10.007</pub-id><pub-id pub-id-type="pmid">29136504</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sze</surname><given-names>CC</given-names></name><name><surname>Shilatifard</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mll3/Mll4/COMPASS family on epigenetic regulation of enhancer function and cancer</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><volume>6</volume><elocation-id>a026427</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a026427</pub-id><pub-id pub-id-type="pmid">27638352</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tschaharganeh</surname><given-names>DF</given-names></name><name><surname>Xue</surname><given-names>W</given-names></name><name><surname>Calvisi</surname><given-names>DF</given-names></name><name><surname>Evert</surname><given-names>M</given-names></name><name><surname>Michurina</surname><given-names>TV</given-names></name><name><surname>Dow</surname><given-names>LE</given-names></name><name><surname>Banito</surname><given-names>A</given-names></name><name><surname>Katz</surname><given-names>SF</given-names></name><name><surname>Kastenhuber</surname><given-names>ER</given-names></name><name><surname>Weissmueller</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>CH</given-names></name><name><surname>Lechel</surname><given-names>A</given-names></name><name><surname>Andersen</surname><given-names>JB</given-names></name><name><surname>Capper</surname><given-names>D</given-names></name><name><surname>Zender</surname><given-names>L</given-names></name><name><surname>Longerich</surname><given-names>T</given-names></name><name><surname>Enikolopov</surname><given-names>G</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>P53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer</article-title><source>Cell</source><volume>158</volume><fpage>579</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.05.051</pub-id><pub-id pub-id-type="pmid">25083869</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tward</surname><given-names>AD</given-names></name><name><surname>Jones</surname><given-names>KD</given-names></name><name><surname>Yant</surname><given-names>S</given-names></name><name><surname>Cheung</surname><given-names>ST</given-names></name><name><surname>Fan</surname><given-names>ST</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Kay</surname><given-names>MA</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Bishop</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Distinct pathways of Genomic progression to benign and malignant tumors of the liver</article-title><source>PNAS</source><volume>104</volume><fpage>14771</fpage><lpage>14776</lpage><pub-id pub-id-type="doi">10.1073/pnas.0706578104</pub-id><pub-id pub-id-type="pmid">17785413</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valekunja</surname><given-names>UK</given-names></name><name><surname>Edgar</surname><given-names>RS</given-names></name><name><surname>Oklejewicz</surname><given-names>M</given-names></name><name><surname>van der Horst</surname><given-names>GTJ</given-names></name><name><surname>O’Neill</surname><given-names>JS</given-names></name><name><surname>Tamanini</surname><given-names>F</given-names></name><name><surname>Turner</surname><given-names>DJ</given-names></name><name><surname>Reddy</surname><given-names>AB</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Histone Methyltransferase Mll3 contributes to genome-scale circadian transcription</article-title><source>PNAS</source><volume>110</volume><fpage>1554</fpage><lpage>1559</lpage><pub-id pub-id-type="doi">10.1073/pnas.1214168110</pub-id><pub-id pub-id-type="pmid">23297224</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>ER</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Sanderson</surname><given-names>BW</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Gogol</surname><given-names>M</given-names></name><name><surname>Alexander</surname><given-names>T</given-names></name><name><surname>Seidel</surname><given-names>C</given-names></name><name><surname>Wiedemann</surname><given-names>LM</given-names></name><name><surname>Ge</surname><given-names>K</given-names></name><name><surname>Krumlauf</surname><given-names>R</given-names></name><name><surname>Shilatifard</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Global analysis of H3K4 methylation defines MLL family member targets and points to a role for Mll1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II</article-title><source>Molecular and Cellular Biology</source><volume>29</volume><fpage>6074</fpage><lpage>6085</lpage><pub-id pub-id-type="doi">10.1128/MCB.00924-09</pub-id><pub-id pub-id-type="pmid">19703992</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JK</given-names></name><name><surname>Tsai</surname><given-names>MC</given-names></name><name><surname>Poulin</surname><given-names>G</given-names></name><name><surname>Adler</surname><given-names>AS</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The Histone demethylase UTX enables RB-dependent cell fate control</article-title><source>Genes &amp; Development</source><volume>24</volume><fpage>327</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1101/gad.1882610</pub-id><pub-id pub-id-type="pmid">20123895</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>JM</given-names></name><name><surname>Hunter</surname><given-names>MV</given-names></name><name><surname>Cruz</surname><given-names>NM</given-names></name><name><surname>Baggiolini</surname><given-names>A</given-names></name><name><surname>Tagore</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Misale</surname><given-names>S</given-names></name><name><surname>Marasco</surname><given-names>M</given-names></name><name><surname>Simon-Vermot</surname><given-names>T</given-names></name><name><surname>Campbell</surname><given-names>NR</given-names></name><name><surname>Newell</surname><given-names>F</given-names></name><name><surname>Wilmott</surname><given-names>JS</given-names></name><name><surname>Johansson</surname><given-names>PA</given-names></name><name><surname>Thompson</surname><given-names>JF</given-names></name><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>Pearson</surname><given-names>JV</given-names></name><name><surname>Mann</surname><given-names>GJ</given-names></name><name><surname>Scolyer</surname><given-names>RA</given-names></name><name><surname>Waddell</surname><given-names>N</given-names></name><name><surname>Montal</surname><given-names>ED</given-names></name><name><surname>Huang</surname><given-names>TH</given-names></name><name><surname>Jonsson</surname><given-names>P</given-names></name><name><surname>Donoghue</surname><given-names>MTA</given-names></name><name><surname>Harris</surname><given-names>CC</given-names></name><name><surname>Taylor</surname><given-names>BS</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Chaligné</surname><given-names>R</given-names></name><name><surname>Shliaha</surname><given-names>PV</given-names></name><name><surname>Hendrickson</surname><given-names>R</given-names></name><name><surname>Jungbluth</surname><given-names>AA</given-names></name><name><surname>Lezcano</surname><given-names>C</given-names></name><name><surname>Koche</surname><given-names>R</given-names></name><name><surname>Studer</surname><given-names>L</given-names></name><name><surname>Ariyan</surname><given-names>CE</given-names></name><name><surname>Solit</surname><given-names>DB</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Merghoub</surname><given-names>T</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name><name><surname>Hayward</surname><given-names>NK</given-names></name><name><surname>White</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Anatomic position determines Oncogenic specificity in Melanoma</article-title><source>Nature</source><volume>604</volume><fpage>354</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04584-6</pub-id><pub-id pub-id-type="pmid">35355015</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Simeone</surname><given-names>DM</given-names></name><name><surname>Sun</surname><given-names>T-T</given-names></name><name><surname>DeGraff</surname><given-names>DJ</given-names></name><name><surname>Tang</surname><given-names>M-S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>X-R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Dominant role of Cdkn2B/P15Ink4B of 9P21.3 tumor Suppressor Hub in inhibition of cell-cycle and Glycolysis</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>2047</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-22327-5</pub-id><pub-id pub-id-type="pmid">33824349</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Yin</surname><given-names>H</given-names></name><name><surname>Tammela</surname><given-names>T</given-names></name><name><surname>Papagiannakopoulos</surname><given-names>T</given-names></name><name><surname>Joshi</surname><given-names>NS</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Bronson</surname><given-names>R</given-names></name><name><surname>Crowley</surname><given-names>DG</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Anderson</surname><given-names>DG</given-names></name><name><surname>Sharp</surname><given-names>PA</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>CRISPR-mediated direct Mutation of cancer genes in the mouse liver</article-title><source>Nature</source><volume>514</volume><fpage>380</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1038/nature13589</pub-id><pub-id pub-id-type="pmid">25119044</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zender</surname><given-names>L</given-names></name><name><surname>Xue</surname><given-names>W</given-names></name><name><surname>Cordón-Cardo</surname><given-names>C</given-names></name><name><surname>Hannon</surname><given-names>GJ</given-names></name><name><surname>Lucito</surname><given-names>R</given-names></name><name><surname>Powers</surname><given-names>S</given-names></name><name><surname>Flemming</surname><given-names>P</given-names></name><name><surname>Spector</surname><given-names>MS</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Generation and analysis of genetically defined liver Carcinomas derived from Bipotential liver Progenitors</article-title><source>Cold Spring Harbor Symposia on Quantitative Biology</source><volume>70</volume><fpage>251</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1101/sqb.2005.70.059</pub-id><pub-id pub-id-type="pmid">16869761</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Sadot</surname><given-names>E</given-names></name><name><surname>Vigidal</surname><given-names>JA</given-names></name><name><surname>Klimstra</surname><given-names>DS</given-names></name><name><surname>Balachandran</surname><given-names>VP</given-names></name><name><surname>Kingham</surname><given-names>TP</given-names></name><name><surname>Allen</surname><given-names>PJ</given-names></name><name><surname>D’Angelica</surname><given-names>MI</given-names></name><name><surname>DeMatteo</surname><given-names>RP</given-names></name><name><surname>Jarnagin</surname><given-names>WR</given-names></name><name><surname>Ventura</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Characterization of hepatocellular adenoma and carcinoma using microRNA profiling and targeted Gene sequencing</article-title><source>PLOS ONE</source><volume>13</volume><elocation-id>e0200776</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0200776</pub-id><pub-id pub-id-type="pmid">30052636</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zindy</surname><given-names>F</given-names></name><name><surname>Eischen</surname><given-names>CM</given-names></name><name><surname>Randle</surname><given-names>DH</given-names></name><name><surname>Kamijo</surname><given-names>T</given-names></name><name><surname>Cleveland</surname><given-names>JL</given-names></name><name><surname>Sherr</surname><given-names>CJ</given-names></name><name><surname>Roussel</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Myc signaling via the ARF tumor Suppressor regulates P53-dependent apoptosis and Immortalization</article-title><source>Genes &amp; Development</source><volume>12</volume><fpage>2424</fpage><lpage>2433</lpage><pub-id pub-id-type="doi">10.1101/gad.12.15.2424</pub-id><pub-id pub-id-type="pmid">9694806</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuber</surname><given-names>J</given-names></name><name><surname>McJunkin</surname><given-names>K</given-names></name><name><surname>Fellmann</surname><given-names>C</given-names></name><name><surname>Dow</surname><given-names>LE</given-names></name><name><surname>Taylor</surname><given-names>MJ</given-names></name><name><surname>Hannon</surname><given-names>GJ</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Toolkit for evaluating genes required for proliferation and survival using Tetracycline-regulated Rnai</article-title><source>Nature Biotechnology</source><volume>29</volume><fpage>79</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1038/nbt.1720</pub-id><pub-id pub-id-type="pmid">21131983</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain and strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Wild-type C57BL/6 J</td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">Stock #000664</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">HLE HCC cell line</td><td align="left" valign="bottom">JCRB Cell Bank</td><td align="left" valign="bottom">JCRB0404</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Myc</italic>; sg<italic>Trp53</italic> HCC cell lines</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">Three independent cell lines derived from different mice were used as biological replicates</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Myc</italic>; sg<italic>Kmt2c</italic> HCC cell lines</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">Three independent cell lines derived from different mice were used as biological replicates</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Myc</italic>; sg<italic>Axin1</italic> HCC cell lines</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">Three independent cell lines derived from different mice were used as biological replicates</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">TRE-sh<italic>Kmt2c</italic>.1 liver progenitor line</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">TRE-sh<italic>Kmt2c</italic>.2 liver progenitor line</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-MLL3/4 (Rabbit polyclonal)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib19">Dorighi et al., 2017</xref>;<break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/28483418/">28483418</ext-link></td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">ChIP-seq (1:500)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pT3-<italic>Myc</italic></td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">#92046</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pT3-<italic>Ctnnb1 N90</italic></td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">#31785</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">PX330-Cas9-U6-sgRNA</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">#42230</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">CMV-SB13</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib32">Huang et al., 2014</xref>;<break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25128497/">25128497</ext-link></td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pT3-EF1a-GFP-miRE</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib32">Huang et al., 2014</xref>;<break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25128497/">25128497</ext-link></td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80854.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Hao</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00t9vx427</institution-id><institution>University of Texas Southwestern Medical Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.06.07.495174" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.06.07.495174"/></front-stub><body><p>This paper convincingly shows that MLL3 regulates the CDKN2A tumor suppressor in MYC-driven liver cancers. The use of in vivo models and epigenomic analysis made the findings particularly robust. This work significantly advances our understanding of the function of MLL3 in cancer.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80854.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Zhu</surname><given-names>Hao</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00t9vx427</institution-id><institution>University of Texas Southwestern Medical Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Zhu</surname><given-names>Hao</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00t9vx427</institution-id><institution>University of Texas Southwestern Medical Center</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Magee</surname><given-names>Jeffrey A</given-names></name><role>Reviewer</role><aff><institution>Washington University School of Medicine</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.06.07.495174">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.06.07.495174v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;MLL3 regulates the <italic>CDKN2A</italic> tumor suppressor locus in liver cancer&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Hao Zhu as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Erica Golemis as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Jeffrey A Magee (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>There are several suggestions or clarifications from each reviewer that need to be addressed; Please address all of the comments from the reviewers.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1. How can we tell that the ChIP-seq signal is not coming entirely from MLL4 in the MYC; sgMLL3 tumors? if the signal is partially or entirely from MLL4, then it is hard to know what amount of binding is contributed by MLL3. Moreover, there could be concomitant up-regulation of MLL4 when MLL3 is deleted.</p><p>2. Figure 1C should have some statistical analysis. The numbers of mice used here are low, so the stats should be included.</p><p>3. Figure 4 D, F, and G would benefit from an increased number of replicates.</p><p>4. Figure S1D is missing &quot;T&quot; for transposons.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. There are no statistical arguments to support the claim that MLL3 and CDKN2A mutations are mutually exclusive in HCC or any of the other cancers that they analyzed. When each mutation is relatively rare, is it that surprising that they do not co-occur? The authors should support this argument with a more rigorous analysis or remove it.</p><p>2. The authors argue that MLL3 binds the CDKN2A promoter, but the ChIP-seq data also show peaks within the gene body. Can they clarify how they distinguish direct interactions between MLL3 and promoter elements from indirect interactions that might occur when enhancers loop and engage the promoter?</p><p>3. The authors should show a Western blot demonstrating specific loss of MLL3 expression in the sgMll3 lines, given that the antibody used for the ChIP-seq studies recognizes both MLL3 and MLL4.</p><p>4. Figures 2C and 3B, C both need clarification. For Figure 2C, what do the values in the heatmap reflect? For Figure 3C, how did they generate the gene set for the GSEA, and what are these comparisons meant to prove? This point did not come through clearly in the manuscript.</p><p>5. The study focuses entirely on MYC-driven HCC, with the exception of the CRISPRa experiments performed in p53/Tert mutant HLE cells. Can the authors comment on whether the MLL3/CDKN2A interaction generalizes to non-MYC-driven HCC?</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>The authors of the manuscript describe an interesting and novel mechanism by which MLL3 regulates the CDKN2A tumor suppressor locus in MYC amplification-dependent liver cancer.</p><p>Overall, the manuscript is well written, organized, and focused on an interesting topic, and with data presented supports the authors' claims. Nevertheless, there are a few concerns that remain in relating to the study, and therefore, need to be addressed further for publication in the <italic>eLife</italic> journal.</p><p>Specific comments:</p><p>1. While the mouse genetic model manipulating the overexpression (OE) of oncogene and knockout of tumor suppressor gene (TSG) is an elegant design to show the combined effects of MYC-OE and MLL3-loss in liver tumorigenesis, it might not be a straightforward idea to use Myc; sgp53 as a control, especially in the ChIP-seq study and the downstream analyses. Because p53 has its own distinct set of targets that may cooperate with MYC and p53 negatively regulates Ink4a and Arf expression, the authors should explain more clearly the rationale for choosing Myc; sgp53, rather than Myc; sgChr8 (only overexpress Myc but does not silence any targets), as a control in the comparison with Myc; sgMll3.</p><p>2. Although the authors provide a potential mechanism for MLL3's tumor suppressive role in MYC-driven tumorigenesis, the clinical relevance is shown in Figure 1A may only fit their hypothesis into a small fraction of human HCC patients due to the relatively low mutation rate of MLL3 (4%) compared to the high MYC amplification/gain mutation rate (41%). In addition, it would be interesting to assess the clinical relevance between amplification/gain mutations of MYC and truncating mutations/deep deletions of MLL3 or CDKN2A in human cancers shown in figures S4C and S4D. This will strengthen their hypothesis that loss of MLL3 or CDKN2A impairs MYC-induced apoptosis, but instead, contributes to MYC-induced tumorigenesis in vivo.</p><p>3. The supplementary experiments described in lines 179 – 188 to &quot;demonstrate a direct transcriptional effect of MLL3 on the Cdkn2a locus&quot; were not very clear and somehow confusing to the reviewer the first time reading and it was unclear why the authors involved p53 and Axin1 targeting in this set of experiments.</p><p>4. The novel findings of this manuscript would be: (i) MLL3 regulates tumor suppressor gene expression via modulating their promoter chromatin landscapes (i.e. H3K4me3), and (ii) loss of normal function of MLL3 or the downstream effector CDKN2A may impair MYC-induced apoptosis, and in turn, lead to MYC-induced tumorigenesis. Thus, it would be better to introduce more background regarding the current knowledge of (i) MLL3's roles in the regulation of enhancer-associated H3K4me1 modulation and somehow unclear but detectable function in promoter-associated H3K4me3 regulation, and (ii) the cellular content-dependent regulation of MYC-induced apoptosis or tumorigenesis. The current introduction is too short.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80854.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>There are several suggestions or clarifications from each reviewer that need to be addressed; Please address all of the comments from the reviewers.</p><p>Reviewer #1 (Recommendations for the authors):</p><p>1. How can we tell that the ChIP-seq signal is not coming entirely from MLL4 in the MYC; sgMLL3 tumors? if the signal is partially or entirely from MLL4, then it is hard to know what amount of binding is contributed by MLL3. Moreover, there could be concomitant up-regulation of MLL4 when MLL3 is deleted.</p></disp-quote><p>We agree that the interpretation may be limited due to the fact that the antibody used for ChIP recognizes both MLL3 and MLL4. Unfortunately, this was the only antibody we found effective for the murine systems after years of trying. Thus, in comparing <italic>Myc</italic>; sg<italic>Kmt2c</italic> tumors, with <italic>Myc</italic>; <italic>sgTrp53</italic> tumors, the unchanged peak signals in some areas of the genome are most likely due to MLL4 binding. It is important to note that this overlapping specificity highlights an exclusive relationship between MLL3 and targets such as <italic>Cdkn2a</italic>, as our RNA-seq data demonstrate that there was no compensatory change in <italic>Kmt2d</italic> (Mll4) expression in <italic>Kmt2c</italic> targeted <italic>cells</italic> (Figure 3—figure supplement 1A), where we observe a dramatic reduction of peaks associated with <italic>Cdkn2a</italic> locus by ChIP-seq. From these results, we conclude that the <italic>Cdkn2a</italic> locus is a tumor suppressive genomic target of MLL3. We acknowledge the limitations of the antibody and how this effects our interpretations in the revised text.</p><disp-quote content-type="editor-comment"><p>2. Figure 1C should have some statistical analysis. The numbers of mice used here are low, so the stats should be included.</p></disp-quote><p>We now include the statistics (the statistical method and <italic>P</italic>-values) in all relevant figures.</p><disp-quote content-type="editor-comment"><p>3. Figure 4 D, F, and G would benefit from an increased number of replicates.</p></disp-quote><p>We repeated the experiments with additional biological replicates (n = 4). Importantly, we also tested an additional sg<italic>Kmt2c</italic> for CRISPRa to demonstrate the effects are not due to one specific guide RNA.</p><disp-quote content-type="editor-comment"><p>4. Figure S1D is missing &quot;T&quot; for transposons.</p></disp-quote><p>We re-made the figure to correct this omission.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. There are no statistical arguments to support the claim that MLL3 and CDKN2A mutations are mutually exclusive in HCC or any of the other cancers that they analyzed. When each mutation is relatively rare, is it that surprising that they do not co-occur? The authors should support this argument with a more rigorous analysis or remove it.</p></disp-quote><p>We agree with the reviewer that the mutually exclusive mutation patterns between <italic>KMT2C</italic> and <italic>CDKN2A</italic> in human cancers are not statistically supported, mainly due to the low mutation frequencies of one or both genes. Thus, we removed the majority of the mutation analyses. The updated oncoprint in HCC is modified to include <italic>MYC</italic> and all the <italic>P</italic>-values of the comparisons of interest.</p><disp-quote content-type="editor-comment"><p>2. The authors argue that MLL3 binds the CDKN2A promoter, but the ChIP-seq data also show peaks within the gene body. Can they clarify how they distinguish direct interactions between MLL3 and promoter elements from indirect interactions that might occur when enhancers loop and engage the promoter?</p></disp-quote><p>We agree with the reviewer that we cannot rule out other possible promoter-engaging mechanisms, such as via MLL3 binding within the gene body and/or looping between promoters and enhancers. To address some of these concerns, we also performed ChIP-seq for several histone modifications that have been widely used to identify different cis-acting elements in the genome and their transcriptional state (H3K4me1 – enhancer, H3K4me3 – promoter, H3K27ac – active enhancer or promoter). We also modified the relevant text in the Results and in the Discussion to incorporate the reviewer’s point.</p><disp-quote content-type="editor-comment"><p>3. The authors should show a Western blot demonstrating specific loss of MLL3 expression in the sgMll3 lines, given that the antibody used for the ChIP-seq studies recognizes both MLL3 and MLL4.</p></disp-quote><p>We agree with the reviewer that a Western blot result would further support our conclusion. To address this, we tried several anti-mouse MLL3 antibodies, including one from Cell Signaling Technology (#53641) and another non-commercially available one that worked for ChIP-seq. Unfortunately, none of these attempts yielded specific bands with correct molecular weight in the immunoblots.</p><disp-quote content-type="editor-comment"><p>4. Figures 2C and 3B, C both need clarification. For Figure 2C, what do the values in the heatmap reflect? For Figure 3C, how did they generate the gene set for the GSEA, and what are these comparisons meant to prove? This point did not come through clearly in the manuscript.</p></disp-quote><p>We thank the reviewer for pointing out the lack of clarity, and we have updated the text in the Results and the Methods to provide the information requested.</p><p>For Figure 2C, the values in the heatmap are the Z-scores of the normalized counts for the peak signals of histone modifications in ChIP-seq data. For GSEA in Figure 3, transcriptional signatures were derived based on significantly changed genes (adjusted <italic>P</italic> &lt;0.05; absolute fold change &gt;2) in RNA-seq on mouse HCC cell lines (<italic>Myc</italic>; sg<italic>Kmt2c</italic> vs <italic>Myc</italic>; sg<italic>Trp53</italic>), and in human HCCs with mutations in <italic>KMT2C</italic> vs. <italic>TP53</italic> (adjusted <italic>P</italic> &lt;0.05; absolute fold change &gt;2). Those signatures were then compared to the transcriptional results on human HCCs with genomic inactivation of <italic>CDKN2A</italic> vs <italic>TP53</italic> in Figure 3B and 3C. We updated Figure 3 to add more relevant details.</p><disp-quote content-type="editor-comment"><p>5. The study focuses entirely on MYC-driven HCC, with the exception of the CRISPRa experiments performed in p53/Tert mutant HLE cells. Can the authors comment on whether the MLL3/CDKN2A interaction generalizes to non-MYC-driven HCC?</p></disp-quote><p>Our study primarily used <italic>Myc</italic> as the driving oncogene for two reasons: first, MLL3 was nominated as a tumor suppressor gene whose loss cooperates with <italic>Myc</italic> oncogene in an in vivo HCC screen (new Figure 1—figure supplement 1); second, in human HCCs, <italic>KMT2C</italic> mutations and deletions co-occur with <italic>MYC</italic> gains and amplification.</p><p>We agree with the reviewer that it is of interest to know whether the results are oncogene independent. Thus, we performed the analogous experiment by HTVI of transposon containing the constitutively active <italic>Ctnnb1</italic>. However, we did not observe oncogenic cooperation between <italic>Ctnnb1</italic> activation and MLL3 loss; no mice developed liver tumors by the experimental endpoint (5 months post HTVI, Figure 1—figure supplement 3). Additionally, analysis of human HCCs showed no significant co-occurrence between <italic>CTNNB1</italic> and <italic>KMT2C</italic> alterations (Figure 1A). These results suggests that, similar to other epigenetic regulators, the tumor-suppressive function of MLL3 is likely oncogene- and context dependent. Recent studies support the notion that chromatin context can favor certain oncogenic alterations and we speculate in the discussion that this may also be true for MLL3. We have updated the text to reflect the context-specificity of MLL3 as a tumor suppressor.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>The authors of the manuscript describe an interesting and novel mechanism by which MLL3 regulates the CDKN2A tumor suppressor locus in MYC amplification-dependent liver cancer.</p><p>Overall, the manuscript is well written, organized, and focused on an interesting topic, and with data presented supports the authors' claims. Nevertheless, there are a few concerns that remain in relating to the study, and therefore, need to be addressed further for publication in the eLife journal.</p><p>Specific comments:</p><p>1. While the mouse genetic model manipulating the overexpression (OE) of oncogene and knockout of tumor suppressor gene (TSG) is an elegant design to show the combined effects of MYC-OE and MLL3-loss in liver tumorigenesis, it might not be a straightforward idea to use Myc; sgp53 as a control, especially in the ChIP-seq study and the downstream analyses. Because p53 has its own distinct set of targets that may cooperate with MYC and p53 negatively regulates Ink4a and Arf expression, the authors should explain more clearly the rationale for choosing Myc; sgp53, rather than Myc; sgChr8 (only overexpress Myc but does not silence any targets), as a control in the comparison with Myc; sgMll3.</p></disp-quote><p>We agree with the reviewer that using <italic>Myc</italic>; sg<italic>Trp53</italic> cells as controls has downsides, due to p53specific tumor suppressive functions. In theory, HCC cell lines with only <italic>Myc</italic> activation would have been ideal. However, as shown in Figure 1, <italic>Myc</italic> activation alone (<italic>Myc</italic>; sg<italic>Chrom8</italic>) does not yield liver tumors from which we could eventually derive cell lines and, even had they occurred, there would likely be selected secondary events.</p><p>We also agree that silencing p53 may result in compensatory upregulation of Ink4a and Arf. However, we performed a number of experiments to validate the ability of MLL3 to directly regulate <italic>Cdkn2a</italic> in p53 null and WT cells (Figure 4—figure supplement 1). We found that targeting <italic>Kmt2c</italic> with 2 sgRNAs reduces p16<sup>Ink4a</sup> and p19<sup>Arf</sup> levels in <italic>Myc</italic>; sh<italic>Trp53</italic> cells (Figure 4—figure supplement 1D), and <italic>Kmt2c</italic> shRNA knockdown reduces Ink4a and Arf transcripts in <italic>Myc</italic>; sg<italic>Axin1</italic> cells where p53 was not altered (Figure 4—figure supplement 1F). All of these observations indicate that the regulation of the <italic>Cdkn2a</italic> locus is MLL3-dependent rather than the result of p53 loss. Lastly, new Figure 4—figure supplement 1G shows that MLL3 binding peaks at <italic>Cdkn2a</italic> locus also exist in <italic>Myc</italic>; sg<italic>Axin1</italic> cells, confirming that our results and conclusions are not exclusive to p53 inactivated cells. We acknowledge these potential confounding issues with compensatory activation of <italic>Cdkn2a</italic> and these confirmatory experiments in the revised text.</p><disp-quote content-type="editor-comment"><p>2. Although the authors provide a potential mechanism for MLL3's tumor suppressive role in MYC-driven tumorigenesis, the clinical relevance is shown in Figure 1A may only fit their hypothesis into a small fraction of human HCC patients due to the relatively low mutation rate of MLL3 (4%) compared to the high MYC amplification/gain mutation rate (41%). In addition, it would be interesting to assess the clinical relevance between amplification/gain mutations of MYC and truncating mutations/deep deletions of MLL3 or CDKN2A in human cancers shown in figures S4C and S4D. This will strengthen their hypothesis that loss of MLL3 or CDKN2A impairs MYC-induced apoptosis, but instead, contributes to MYC-induced tumorigenesis in vivo.</p></disp-quote><p>We thank the reviewer for these constructive suggestions. We recognize the limitations of our previous analyses of <italic>KMT2C</italic> and <italic>CDKN2A</italic> mutations in different cancer types. Because <italic>MYC</italic> is a recurrent oncogene in some but not all cancer types, we focused the analysis to show statistically significant cooccurrences between <italic>MYC</italic> and <italic>KMT2C</italic>/<italic>CDKN2A</italic> mutations in HCC, and removed the less relevant oncoprints.</p><disp-quote content-type="editor-comment"><p>3. The supplementary experiments described in lines 179 – 188 to &quot;demonstrate a direct transcriptional effect of MLL3 on the Cdkn2a locus&quot; were not very clear and somehow confusing to the reviewer the first time reading and it was unclear why the authors involved p53 and Axin1 targeting in this set of experiments.</p></disp-quote><p>We apologize for the confusion, and thank the reviewer for pointing it out. As referred to in our response to the first point, it is documented that p53 loss could result in activation of Ink4a and Arf. To rule out such a possibility, we targeted <italic>Kmt2c</italic> by CRISPR in <italic>Myc</italic>; sh<italic>Trp53</italic> cells to demonstrate that MLL3 controls p16<sup>Ink4a</sup> and p19<sup>Arf</sup> expression in p53-suppressed tumor cells. Moreover, both shRNA knockdown of <italic>Kmt2c</italic> and ChIP-seq on MLL3 in <italic>Myc</italic>; sg<italic>Axin1</italic> cells further show that the regulation of <italic>Cdkn2a</italic> by MLL3 is independent of p53 status. We have modified the text to more accurately and clearly reflect our results.</p><disp-quote content-type="editor-comment"><p>4. The novel findings of this manuscript would be: (i) MLL3 regulates tumor suppressor gene expression via modulating their promoter chromatin landscapes (i.e. H3K4me3), and (ii) loss of normal function of MLL3 or the downstream effector CDKN2A may impair MYC-induced apoptosis, and in turn, lead to MYC-induced tumorigenesis. Thus, it would be better to introduce more background regarding the current knowledge of (i) MLL3's roles in the regulation of enhancer-associated H3K4me1 modulation and somehow unclear but detectable function in promoter-associated H3K4me3 regulation, and (ii) the cellular content-dependent regulation of MYC-induced apoptosis or tumorigenesis. The current introduction is too short.</p></disp-quote><p>We thank the reviewer for this suggestion. We have revised the Introduction to weave in these two points.</p></body></sub-article></article>